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Preface
The previous Core Curriculum for the General Cardiologist defined
a model for cardiology training in Europe and it has been adopted
as the standard for regulating training, for access to the specialty
(certification), and for revalidation in several countries.1
During the last 5 years we have witnessed profound changes in
cardiological practice. The work of both hospital and independent
cardiologists has been better integrated with that of general practi-
tioners. It has taken intoaccount the requirementsof national author-
ities, re-imbursement organizations, and hospital administrations.
Cardiologists face changing patient expectations. General cardiolo-
gists, interventional cardiologists, anaesthetists, and cardiac surgeons
work together in Heart Teams.2,3 The age of cardiac patients has
increased and they are presenting with more co-morbidities. Knowl-
edge, technology, and treatment are constantly advancing: new
imaging modalities have become widely available. Stent technology
has evolved and competes with cardiac surgery for all but complex
cases.2 Percutaneous valve implantations are increasingly successful.4
Interventional electrophysiology and device therapy have become
cornerstones in the practice of cardiology.5,6 Care of the patient
with heart failure is now a multi-disciplinary undertaking.7 New
powerful anti-thrombotic and anticoagulant therapies have been
introduced and are often used in combination, with clear benefits
but increased bleeding risks.6,8,9 Use of diagnostic and therapeutic
tools and the approaches to management of common conditions
havebeen systematically clarified in regularly updatedESCconsensus
guideline documents.
Against thebackgroundof thesedevelopments, theBoardof theESC
decided in 2011 to revise and update the Core Curriculum. The chair-
man of the Committee for Education 2010–2012, Otto A. Smiseth,
delegated this project to a task force, whose members were drawn
from general cardiologists. The 2013 version of the Core Curriculum
outlines the knowledge and skills of the general clinically oriented cardi-
ologist, rather than those required for the sub-specialties. The docu-
ment provides a framework for training and certification, continuous
medical education (CME), and recertification.
TheCoreCurriculumwill inevitably continue to evolve as authors
and reviewers are aware that there are still important differences in
training and means throughout Europe and ESC member states. In
the Core Curriculum, the ESC is setting a standard that national so-
cieties can use in their dealings with political institutions and national
authorities. A deliberate decision was taken to outline an optimal
rather than a minimum standard, allowing for the fact that not
every training system will be able, or may not wish, to adopt the full
curriculum. In countries (or centres) that are currently unable to
deliver training in all its aspects, the Core Curriculum can and
should be used as a benchmark to promote improvement.
The 2013 Core Curriculum defines the clinical, patient-oriented,
training of the general cardiologist. The overall structure of the pre-
vious version has been retained, but the table format has been aban-
doned to limit the number of printed pages and to make the
document more easily searchable on-line. In most subject areas,
there was a wide if not unanimous consensus among the task force
members on the training required for the cardiologist of the future.
The document recommends that acquisition of competence in
general cardiology requires at least 6 years of full-time postgraduate
training, of which 4 years are devoted to cardiology.
The general aspects of training and all individual chapters have
been updated. The document focuses on knowledge of mechanisms
of disease, clinical and communication skills, empathy for the patient
and their relatives, and teamwork. A clear boundary has been set
between the competencies required of the general cardiologist and
those of the sub-specialist.10–13 The first part of the curriculum
coversgeneral aspectsof training, and is followedbyacomprehensive
description of the specific components in 28 chapters. Each of
the chapters includes statements of the objectives, and is further sub-
divided into the required knowledge, skills and behaviours, and
attitudes.
Some chapters have been renamed and/or sub-divided into
sub-sections. The most salient changes are summarized here. Non-
invasive imaging (Chapter 2.3) has been divided into five sections:
Non-invasive imaging (general aspects), Echocardiography, Cardiac
magnetic resonance (CMR), Cardiac X-ray computed tomography,
and Nuclear techniques. Cardiovascular prevention (Chapter 2.7)
has been divided into sections on Cardiovascular risk factors and
Arterial hypertension. Cardiac tumours (Chapter 2.12) has been
replaced by a new and broader chapter on Oncology and the
heart. The chapter Cardiac Rehabilitation and Exercise Physiology
(Chapter 2.19) has become Physical activity and Sport in primary
and secondaryprevention and includes sectionsonSports cardiology
and Cardiac rehabilitation. A new chapter entitled Acute cardiovas-
cular care (Chapter 2.27) has been added. The Cardiac consult
(Chapter 2.28) has been expanded and divided into sections
dealing with the patient undergoing non-cardiac surgery, the
patient with neurological symptoms or diseases, and the patient
with conditions not presenting primarily as cardiovascular disease
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[elderly patients, patients with diabetes, chronic kidney disease
(CKD), erectile dysfunction, and others].
The 2013 Core Curriculum underwent a thorough review process
based on the template of the review of the ESC guidelines. The docu-
ment does not include minimum or optimal numbers of procedures
to be undertaken, and does not address periodic evaluation, certifica-
tion, or revalidation. This does not obviate the importance of regular,
structured, and formallydocumentedassessment,which is crucial to im-
plementation of the curriculum. This should include knowledge-based
assessments (formative and summative), formally observed procedures
andpractices, a log-book, andarecognitionof thepotentialof simulation
techniques in both training and assessment.
Part 1: The Core Curriculum for
the General Cardiologist
1.1 The general cardiologist and his
clinical field
The clinical specialty of cardiology aims to deliver expert care for
patients presenting with disorders of the heart, the systemic, and
the pulmonary circulations. This Core Curriculum provides the
standards for training in general cardiology, as well as a template
for the maintenance of competence for qualified cardiologists.
Completion of the curriculum in general cardiology should equip
the trained cardiologist with the knowledge, skills, behaviours, and
attitudes to act independently as an expert in the
† diagnosis, assessment, and management of cardiovascular emer-
gencies;
† diagnosis, assessment, and management of patients referred
fromprimary care or othermedical specialties with knownor sus-
pected disorders of the heart and circulation; and
† risk assessment and the prevention of cardiovascular disease in
their community and in their patients.
The ability to apply knowledge to clinical problems requires mastery
of the indications for, and the performance and interpretation of
cardiological investigations, treatments, and procedures. It further
demands a depth of knowledge and experience of the sub-specialties
sufficient to ensure the appropriate referral for more advanced
investigations and therapies.
The content of the 2013 Core Curriculum is inspired by the
most recent ESC Guidelines for Clinical Practice.4,6,7,9,14,15 These
guidelines constitute an authoritative, comprehensive, and
updated library of cardiac evidence-based medicine. The previous
version of theCoreCurriculumwas an important source of informa-
tion for the structure and content of the European Textbook of
Cardiology.
The general cardiologist is a medical specialist with a thorough
basic training in internal medicine, experience of which is particularly
relevant in the fields of intensive care, pulmonary diseases, kidney
diseases, diabetes care, and care for the elderly. The most common
cardiovascular diseases are consequences of atherosclerosis, arterial
hypertension, ageing, heart failure, and rhythm or conduction distur-
bances. Cardiologists will often have to be involved (in collaboration
with the general practitioner and other care providers) in the global
care of patients, beyond their primary responsibility for diseases of
the heart and circulation.
In many EU and ESC member countries, office-based general car-
diologists work in isolation or in group practices outside hospitals,
and serve a network of general practitioners. They perform general
cardiac evaluation and treatment of patients with suspected or
established cardiovascular disease using non-invasive methods.
Office-based general cardiologists have a pivotal role in the interplay
between general practitioners and hospitals with more advanced
functions. In small- andmedium-sized hospitals, the general cardiolo-
gist is the core of the cardiology department. In cardiovascular
centres within larger hospitals (referral centres), the general cardi-
ologist may be (but is not necessarily) the coordinator of the activity
of general cardiologists and sub-specialists. He or she then has the
primary responsibility for the development and application of clinical
care pathways. The general cardiologist is a team-worker who
interacts closely with sub-specialty cardiologists, other medical
specialties, nurses, paramedics, and other healthcare professionals.
Advances in technology call for sub-specialization inmany areas of
cardiology, especially in those where skills are highly dependent on
the number of examinations or interventions performed, such as in
cardiovascular X-ray computed tomography, magnetic resonance
imaging, interventional cardiology, electrophysiology, and acute
cardiovascular care. This natural and unavoidable evolution of the
cardiological specialty requires team working between cardiologists
with different profiles and with related specialties.
The process for medical decision-making and patient informa-
tion is guided by the ‘four principles’ approach to healthcare
ethics: autonomy, beneficence, non-maleficience, and justice. Trai-
nees in cardiology need to develop skills in the different roles of a
physician. These roles are the physician as a care provider, as a sci-
entist, as a communicator, as a manager, as a collaborator, as a
scholar, and as a health advocate.16 All aspects of theCoreCurricu-
lum fit under the umbrella of one or more of these roles. The car-
diologist must know the indications, strengths, and limitations of
every examination and intervention; such knowledge can be
derived from a solid background in research methodology and sta-
tistics. Cost-effectiveness is increasingly important and should be a
consideration in all medical decisions. Patient safety should be a
permanent concern. The cardiologist must be an effective commu-
nicator; at all stages of the clinical process it is essential to be able to
explain, in layman’s terms, the significance of the findings and their
implications. Skill is required tomanage amedical problemwhilst, at
the same time, managing the cardiologist’s relationship with the
patient and relatives with empathy and respect for their socio-
economic, ethnical, cultural, and religious background. Skilful com-
munication serves to relieve uncertainty, to support the patient
who is facing a poor prognosis or experiences complications or
an unsuccessful intervention, and to sustain adherencewith lifestyle
and pharmacological therapy. Cardiologists often face difficult deci-
sions relating to resuscitation and the implementation of advanced
therapies or transfer to the intensive care environment; they must
be able to maintain the dialogue with and trust of the patient and
relatives in these circumstances, and attempt to anticipate when
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they may, or may not, accept a suggestion for conservative therapy
or palliative care. In this document,we insist heavily on the physician
as a team player. In many clinical settings, the indications for an in-
vasive diagnostic procedure or intervention may be unambiguous,
but in other situations there will be differences in opinion, local ex-
pertise, and logistics that necessitate a concerted multi-disciplinary
approach, derived from assessment by a Heart Team.2,3 The cre-
ation of a Heart Team, which includes general cardiologists, inter-
ventional cardiologists, anaesthetists, cardiac surgeons and other
care providers, serves the purpose of a balanced decision-making
process. Additional inputmay be needed fromgeneral practitioners
and other medical and paramedical care providers. Patients and
their relatives play a crucial role and need help in making informed
decisions about their treatment. The most valuable advice will, in
most instances, be provided to thembywayof a consensus decision
of the Heart Team.
Cardiologists handle sensitive personal data on their patients.
Thesedata shouldbeprotectedwith theutmost confidentiality, in ac-
cordance with personal data protection legislation in the European
Union.
The general cardiologist may decide, after completion of training,
to develop additional knowledge and skills. The areas of specialized
experience currently include
(a) interventional cardiology;
(b) electrophysiology and device therapy;
(c) cardiovascular imaging (echocardiography, cardiac X-ray CT,
CMR, nuclear and PET scan);
(d) cardiovascular intensive care;
(e) advanced heart failure and transplantation;
(f) cardiac rehabilitation and prevention;
(g) grown-up congenital heart disease (GUCH).
The additional knowledge and skills may be acquired in part during
the training in general cardiology, but full expertise and certification
in eachof these areaswill requireadditional training, eitheras partof a
focused sub-specialty programme or as CME. The Core Curriculum
for the general cardiologist includes a depth of knowledge of the sub-
specialties, sufficient to ensure that patients are referred appropri-
ately formore advanced investigations and therapies. The specialized
expertise required for these different domains of cardiology is not
included in the Core Curriculum.
Assessment of competence is not included in the present
document. This does not obviate the importance of regular,
structured, and formally documented assessment, which is crucial
to implementation of the curriculum. This should include assess-
ments of knowledge (formative and summative), formally observed
procedures and practices, (online) log-books and, where available,
the use of simulators (which are applicable both to training and
assessment).
The training should imbue the cardiologist with the habit of life-
long learning and enable them to improve their knowledge of and
experience in the practice of cardiology, to adapt to technological
innovations, to provide the educational and experiential preparation
necessary to underpin progression, where desired, to further
sub-specialty training and, above all, to respond to the changing
expectations of society. Throughout the training programme, and
afterwards, the cardiologist should apply the best available evidence
to deliver optimal patient-centred care, following the principles of
evidence-basedmedicine as developed in theClinical PracticeGuide-
lines of the ESC.
1.2 General aspects of training in the
speciality
Candidates for training should be physicians licensed to practice in
the country of training. The traineemust have the necessary linguistic
ability to communicatewith patients and colleagues in the country of
training and later in the country of practice.
It is understood that a common trunk of general professional
training should be completed before postgraduate specialist training
is undertaken. General training should include the acquisition of
extensive knowledge of and exposure to the acute and chronic
presentations of a broad range of medical conditions.
Learning objectives should be clearly defined, and are preferred to
recommendations based solely on the time spent in a particular
department or on the number of procedures performed. The objec-
tives should include knowledge, and specific and generic skills including
communication and appropriate behaviours and attitudes that will
further be reinforced during ongoing training.
The recommended duration of postgraduate education
is a minimum of 6 years, to include 2 years of common
trunk (internal medicine and/or related specialties) and
a minimum of 4 years of full-time and exclusive training
in cardiology.
To gain sufficient experience, the trainee should be involved in the
management of an appropriate mix and number of in-patients and
outpatients, including the following elements:
† participation in the clinical management of in-patients, including
the coronary care unit and provision of cardiac consultations for
other departments, should constitute a substantial part of the
training programme;
† supervised involvement in themanagement of outpatients, includ-
ing new and return cases, should be undertaken at least once a
week throughout the programme;
† a regular on-call commitment for cardiology (rather than general
internalmedicineorunselectedmedical emergencies) throughout
the programme;
† at least 2 h a day in structured learning, under the direct supervi-
sion of the educational supervisor, which may include:
– explicit learning: journal clubs, methodology of research and
statistics, postgraduate teaching, training in communication
skills, exercises in evidence-based medicine, discussion of
guidelines for clinical practice;
– implicit learning: rounds, case-based discussions, supervised
acquisition of diagnostic, and therapeutic skills.
† basic, clinical, and/or translational research in cardiovascular
medicine should be an inherent part of the cardiovascular training
programme. The Core Curriculum insists on the importance of
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stimulating trainees to participate in basic or clinical research and
to develop a critical and research-oriented approach to clinical
practice. When cardiovascular research is performed on a full-
time basis or to an extent that prevents sufficient progression
of clinical training, adaptation of the total training time must be
considered;
† the training programme should be clearly defined for each individ-
ual, incorporate a periodic review of their progress, and formal
assessment at least once a year.
1.3 Requirements for training institutions
and trainers
1.3.1 Requirements for training institutions
† Training institutions should be recognized by a National Training
Authority as being competent to provide a complete training pro-
gramme, either in the same centre or in collaborationwith others.
It is highlydesirable for the trainees tobeexposed toothermedical
specialties throughout their postgraduate education;
† The ideal situation for a training programme is within a comprehen-
sive heart centre where all aspects of cardiovascular disease are
managed. However, it can happen that not every aspect of training
is accessible at a single site; in these circumstances, rotation through
different institutions or sessional attendance in centres providing
sub-specialties or technologies that are not widely available, may
need to be incorporated into the programme;
† Training institutions should have a library and internet facilities
offering access to the currentworld scientific literature, specifical-
ly major international journals relating to cardiology and internal
medicine, and shouldprovide thenecessaryphysical infrastructure
for training including conference rooms and allocated office space
for trainees;
† The training institution alone or as part of a structured and orga-
nized collaboration should have the necessary facilities to ensure
that trainees can fulfil all aspects of the Core Curriculum with a
sufficient number of patients and procedures for developing the
required skills:
– a fully equipped facility for treating outpatients and emergencies;
– a sufficient number of beds for in-patients;
– a coronary care unit with at least six beds with electrocardio-
graphic and haemodynamic monitoring, and facilities for anti-
bradycardia pacing, cardioversion, and defibrillation. Exposure
to more intensive therapy (e.g. assisted ventilation and ultrafil-
tration) and haemodynamic support devices (intra-aortic
balloon pumps, assist devices, and haemofiltration) should be
available at some time during the training;
– equipment should be available for all typesof non-invasive diag-
nostic and therapeutic procedures including X-ray, electrocar-
diogram (ECG), exercise and pharmacological stress testing,
cardiopulmonary exercise testing (CPX), ambulatory ECG
monitoring, echocardiography and trans-oesophageal echo-
cardiography (TOE), reading and programming of implanted
pacemakers and cardiac defibrillators, CMR imaging, cardiac
X-ray computed tomography, and nuclear medicine. The
institution must have facilities for invasive cardiology, including
diagnostic and therapeutic cardiac catheterization, and electro-
physiological studies;
– the programme must incorporate an institution providing
cardiac surgery for an optimal daily functioning of the Heart
Team.
† The trainee should be provided with the opportunity to partici-
pate in basic scientific or clinical research. If basic science research
facilities are not available in the training institution, collaboration
with centres that offer this option should made available for the
trainee.
1.3.2 Requirements for trainers
Trainers should be recognized by the National Training Authorities
and supervision of training should be available at all times.
There should be a minimum number of expert cardiologists in the
training institution to ensure training in all areas included in the Core
Curriculum.
Ideally the number of trainees should not exceed the number of
trainers (full-time equivalent). This number includes trainees in
general cardiology, postgraduate trainees in cardiology sub-
specialties, residents in internal medicine or related specialties, visit-
ing fellows, and others. Delivery of the curriculum may be facilitated
by a structure that includes a Director of Training (National/Region-
al), a Training Mentor (or educational supervisor), and multiple
Clinical Trainers (or clinical supervisors). The training mentor
(or someone else involved in the organization of training) should
be responsible for organizing the training programme in general
cardiology, coordinating external rotations to referral centres,
attendance at courses and congresses, and organizing structured
learning. It is necessary that both trainee and training mentors are
subject to periodic assessment.
1.4 Learning objectives
Theseare specific statementsof intent,whichexpresswhat the learner
will be able to do at the end of the educational intervention. They are
framed in termsof trainees’ capabilities in specific tasks.Objectives are
classified under the headings of knowledge, skills, and behaviours and
attitudes. Each objective defines what is to be achieved.
Knowledge: The knowledge base trainees require. The subject matter
is defined by the ESC Core Curriculum chapters. This knowledge
includesmechanismsof diseases as the rational basis for long-term
learning.
Skills: The effective application of knowledge to problem solving,
clinical decision-making, and performing procedures, acquired
from experience and training.
Behaviours and attitudes: The attitudes that underlie best behaviour in
clinical practice that trainees need to develop and demonstrate
Categories and levels of competence
This section of the curriculum describes the different levels of com-
petence expected for skills related to investigations and procedures.
These are defined as follows:
Level I: experience of selecting the appropriate diagnostic or thera-
peutic modality and interpreting results or choosing an appropri-
ate treatment for which the patient should be referred. This level
of competency does not include performing a technique, but par-
ticipation in procedures during training may be valuable;
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Level II: level II goes beyond Level I. In addition to Level I require-
ments, the trainee should acquire practical experience but not
as an independent operator. They should have assisted in or per-
formed a particular technique or procedure under the guidance
of a trainer. This level also applies to circumstances in which the
trainee needs to acquire the skills to perform the technique inde-
pendently, but only for routine indications in uncomplicated cases;
Level III: level III goes beyond the requirements for Level I and II. The
trainee must be able independently to recognize the indication,
perform the technique or procedure, interpret the data, and
manage the complications.
Level of competence of cardiological skills
The table summarizes the level of competence that the ESC consid-
ers desirable for a trainee in general cardiology to achieve; those
sub-specializing in a particular aspect of cardiology will require the
highest levels of competence in the relevant techniques, necessitating
a longer duration of training. It is appreciated that the organization of
cardiac services and the resources for training are not uniform
throughout Europe and ESC member states, but the Core
Curriculum aspires to an optimal, rather than a minimal, standard.
In countries (or centres) that are currently unable to deliver training
in all its aspects, theCoreCurriculum should be used as a benchmark
to promote policies for improvement. Rotation of trainees between
different centres can, in most situations, provide an adequate
solution.
First-hand exposure and practical experience play an important
role in the learning of techniques. In this document we focus on
the acquisition of skills rather than on numbers. The number of
procedures engaged in by trainees is important but is not in itself a
robust measure of competence.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Technique Description of competence Level of
competence
ECG Competent in all aspects Level III
Long-term ECG methodologies Competent in all aspects Level III
Exercise ECG testing Competent in all aspects Level III
Cardiopulmonary exercise testing Able to perform and interpret independently in routine cases Level II
Ambulatory BP monitoring Competent in all aspects Level III
Trans-thoracic echocardiography Competent in all aspects Level III
Vascular ultrasound Able to perform and interpret independently in routine cases Level II
Trans-oesophageal echocardiography Able to perform and interpret independently in routine cases Level II
Stress-echocardiography Some practical experience but not as an independent
operator
Level II
Nuclear studies Able to interpret the data independently Level II
Cardiac X-ray computed tomography Able to interpret the data independently Level II
Cardiovascular magnetic resonance Able to interpret the data independently Level IIa
Venous and arterial puncture Competent in all aspects Level III
Invasive haemodynamics including right heart and pulmonary artery
catheterization
Competent in all aspects Level III
Coronary and LV angiography Competent in all aspects Level III
Percutaneous intervention Having assisted at procedures Level I
Cardiac surgery Having assisted at procedures Level I
Temporary pacemaker implantation Competent in all aspects Level III
Pacemaker programming Competent in all aspects Level III
ICD/CRT programming Some practical experience Level II
Pacemaker implantation Practical experience in uncomplicated cases Level II
ICD implantation Having participated at procedures Level I
CRT implantation Having participated at procedures Level I
Electrophysiological studies Some practical experience; able to understand
electrophysiological tracings
Level II
Electrophysiological interventions Having participated at procedures Level I
Electrical cardioversion Competent in all aspects Level III
Pericardiocentesis Competent in all aspects Level III
aThis level II for CMR is in accordance with level 1 of the document ‘Training and accreditation in cardiovascular magnetic resonance in Europe: a position statement of the working
group on cardiovascular magnetic resonance of the European Society of Cardiology’.17
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Part 2: The Core Curriculum
per Topic
2.1 History taking and clinical
examination
Objectives
History taking
To establish a relationship with the patient based on empathy
and trust and to obtain a clinical history relevant to cardiovascular
disorders, including:
† the patient’s spontaneous account of symptoms;
† questions from the cardiologist focused on the presence or
absence of possible cardiovascular symptoms;
† the past medical history;
† cardiovascular risk factors and reversible causes forcardiovascular
diseases;
† symptoms of any co-morbidities;
† family history (cardiovascular and other diseases);
† current and past drug therapy;
† social history (including patient’s socio-economic situation,
professional, educational, and religious background).
Clinical examination
It is emphasized that the trainee should complement the subjective
findings from the clinical historywith the objective findings on clinical
examinationof the cardiovascular system, to establish a diagnosis and
management plan:
† toperformageneral examinationof the patient searching forman-
ifestationsof cardiovascular disease and/orevidenceof co-existing
illness;
† to examine the heart;
† to examine the vascular arterial and venous systems.
Knowledge
History taking
† Range and meaning of words used by patients to describe their
symptoms;
† Several symptoms of cardiovascular disease and features that
differentiate them from non-cardiovascular conditions;
† Cardiovascular risk factors derived from the patient’s history and
the importance of global cardiovascular risk assessment;
† Names, pharmacology, and side-effects of the drugs prescribed to
cardiovascular patients;
† Clinical manifestations and treatment of the co-morbidities often
associated with cardiovascular disease;
† Clinical manifestations and treatment of inherited cardiovascular
diseases and the principles of family counselling.
Clinical examination
† Blood pressure (BP) measurement: principles and limitations of
its diagnostic and prognostic values, keeping in mind the high
variability of clinic BP;
† Characteristics of the normal and abnormal arterial pulse, heart
rate, and rhythm;
† The normal and abnormal precordial impulse;
† Heart auscultation in relation to the cardiac cycle in health and
disease;
† Right atrial pressure (jugular venous pressure);
† Palpation and auscultation of arteries. Significance of abnormal
arterial pulses and vascular bruits at various sites;
† Ankle–brachial index (ABI) as an indication of advanced periph-
eral arterial disease;
† The venous system;
† Clinical signs of under-perfusion and fluid retention;
† Features on general examination caused by cardiovascular disease
(lungs, liver, skin, and limbs).
Skills
History taking
The ability to:
† analyse the information obtained from a patient’s history and inte-
grate it with the clinical examination, in order to develop an
overall assessmentand toestablishadiagnostic and therapeuticplan;
† clarify important clinical information;
† evaluate cardiovascular risk using established risk scores.
Clinical examination
The ability to:
† make and record accurate observations about the clinical state of
the patient, with particular emphasis on the cardiovascular system
in health and disease;
† perform a thorough clinical (and basic neurological) examination;
special emphasis on palpation and auscultation of heart, lungs, and
arteries, inspection of venous pulse, evaluation of liver enlarge-
ment, ascites, and oedema;
† record the history and findings on clinical examination in a struc-
tured electronic or written file.
Behaviours and attitudes
† Consideration for the patient in order to allow sufficient time to
describe symptoms in their own words;
† Willingness to document past-history from general practitioners
† Sensitivity in asking direct and open-ended questions;
† Willingness to contribute in collaboration with the general practi-
tioners, to the global rather than solely the cardiovascular care of
the patient;
† Empathy and respect for patients’ socio-economic, ethnical,
cultural, and religious background;
† Examination of patients with due regard for their dignity.
2.2 The electrocardiogram
Objectives
To select, perform, and interpret each of the non-invasive ECG
techniques:
† standard 12-lead ECG;
† long-term ambulatory ECG;
† exercise ECG testing;
† cardio-pulmonary exercise testing (CPX)10.
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Knowledge
12-Lead ECG
† The cellular and molecular mechanisms involved in the electrical
activity of the heart;
† The anatomy and physiology of the conduction system;
† The electrical vectors throughout the cardiac cycle;
† The normal ECG and how it derives from electrical vectors;
† Common artefacts and lead reversal ECGs;
† The characteristic appearances of, and explanation for, the ECG in
patients with:
(a) chamber hypertrophy;
(b) ischaemia and infarction;
(c) 15-or18-leadECGscanbeperformedwithanalternateprecor-
dial lead placement to assess posterior- or right-sided disease;
(d) conduction disturbances
(i) left bundle branch block, right bundle branch block;
(ii) hemi-fascicular block;
(iii) other types of intraventricular conduction delay;
(iv) AV-block;
(e) tachycardias and bradycardias;
(f) pre-excitation;
(g) chanellopathies
(i) QT abnormalities (short QT, long QT);
(ii) Brugada ECG pattern;
(iii) early repolarization;
(h) other repolarization disturbances
(i) electrolyte abnormalities;
(ii) anti-arrhythmic and other drugs;
(iii) hypothermia;
(i) pericarditis, pericardial effusion, myocarditis;
( j) arrhythmogenic cardiomyopathy;
(k) pacemaker, ICD, and CRT devices and their dysfunction.
Long-term ambulatory ECG
† The indications;
† The limitations.
Exercise ECG testing
† The main indications
– evaluation of ischaemia;
– evaluation of treatment response;
– evaluation of functional capacity (CPX);
– evaluation of inducible arrhythmias;
– evaluation of non-invasive haemodynamic response to exer-
cise (e.g. chronotropic response, BP response);
† Contraindications;
† Criteria for stopping the test;
† Complications and their management.
Cardiopulmonary exercise testing
† The main indications
(a) evaluation of exercise tolerance;
(b) differentiation between cardiovascular and pulmonary
aetiology of exercise intolerance;
(c) anaerobic threshold and aerobic capacity, VE/VCO2 slope;
(d) evaluation of patients with cardiovascular diseases
(i) functional evaluation and prognosis in patients with heart
failure;
(ii) selection for cardiac transplantation;
(iii) monitoring cardiac rehabilitation.
Skills
12-Lead ECG
The ability to:
† perform and systematically interpret the ECG in the clinical
context.
Long-term ambulatory ECG
The ability to:
† perform and interpret ambulatory ECGs.
Exercise ECG testing
The ability to:
† perform and interpret the exercise ECG test in the clinical context;
† manage complications andcarryoutCPRand advanced cardiac life
support (ACLS).
Cardiopulmonary exercise testing
† Perform and interpret CPX in routine cases.
Behaviours and attitudes
† Awareness of the influence of pre-test probability on post-test
probability (Bayes’ law);
† Encouragement and reassurance to the patient throughout the
examination.
2.3 Non-invasive imaging
2.3.1 Non-invasive imaging in general
Objectives
† To select the appropriate imaging modalities according to the
clinical condition:
– non-invasive imaging in general;
– echocardiography of heart and vessels;13
– cardiac magnetic resonance (CMR);17
– cardiac X-ray computed tomography (CT);
– nuclear techniques.
† To interpret and integrate the results into individual patient care;
† To perform most TTE and routine TOE echocardiographic
examinations independently.
Knowledge
† Use of these modalities to assess cardiac structure and function
– cardiac chamber size and wall thickness;
– left ventricular (LV) mass;
– ventricular and atrial volumes;
– measurement of LV and right ventricular (RV) systolic function;
– assessment of LV and RV diastolic function;
– assessment of valvular stenosis;
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– assessment of valvular regurgitation;
– assessmentof coronary artery disease, including calcificationof
coronary arteries (+calcium score); non-invasive angiogram;
– evaluation of the ischaemic myocardium, including regional
wall motion abnormalities, scar, stunning, hibernation, perfu-
sion, and viability;
– myocardial disease;
– pericardial disease;
– cardiac tumours/masses;
– congenital heart disease;
– estimation of shunt size and consequences;
– thoracic and abdominal aortic diseases;
– diseases of the pulmonary circulation;
– the effects of surgical and interventional procedures.
† Use of these modalities to assess vascular anatomy and function
– carotid and vertebral arteries (cervical arteries);
– thoracic and abdominal aorta;
– peripheral arteries;
– lower limb venous system.
† Principles of stress testing as applied in cardiac imaging, including
– treadmill and bicycle exercise;
– vasodilator stress (dipyridamole, adenosine, and related agents);
– sympathomimetic stress (dobutamine).
† Knowledge of radiation exposure with different imaging
techniques and principles of radiation protection.
Skills
The ability to:
† choose the appropriate imaging techniques for specific clinical situa-
tions, utilizing a thorough understanding of the Bayesian approach;
† choose the appropriate stress technique for a particular patient;
† interpret results of imaging examinations and extract prognostic
information;
† ensure safety through:
– application of the principles of radiation and magnetic reson-
ance safety;
– preparation of the patient;
– prevention, detection, and treatment of contrast-induced
nephropathy;
– use of correct acquisition protocols and technologies to
reduce radiation dose.
Behaviours and attitudes
† Selection of imaging techniques, modalities, and protocols in a
clinically useful and cost-effective way, avoiding over- and under-
utilization of tests and, where applicable, keeping inmind radiation
exposure;
† Recognition of strengths and weaknesses of the different non-
invasive imaging modalities in specific clinical situations.
2.3.2 Echocardiography
Knowledge
† Techniques:
– M-mode;
– two- and three-dimensional (2D and 3D) modes;
– Doppler imaging (blood flow, tissue);
– ultrasound examination of arteries and veins;
– contrast echocardiography;
– trans-oesophageal echocardiography (TOE);
– deformation imaging (speckle-tracking- and Doppler-based
strain analysis);
– stress-echo modalities (exercise and/or pharmacological echo).
† Cardiac indications:
– global left ventricular (LV) and right ventricular (RV) systolic
and diastolic function;
– regional LV function, including ischaemic regional wall motion
abnormalities and their implications for the presence of scar,
stunning, hibernation, perfusion, and viability;
– LV mass, scaling for body size, and hypertrophy;
– cardiac chambers anatomy, size, function;
– primary and secondary cardiomyopathies (dilated, hyper-
trophic, restrictive, arrhythmogenic);
– valvularmorphologyand function, including stenosis and regur-
gitation, multivalvular diseases;
– valve repair, valve prostheses, percutaneous valve implantation;
– endocarditis;
– pericardial disease (including cardiac tamponade);
– cardiac masses (tumours, thrombi, vegetations, foreign bodies);
– congenital heart disease before and after surgical correction;
– shunt lesions;
– pulmonary hypertension;
– non-invasive haemodynamics, including cardiac output, LV
filling pressures, pulmonary artery pressure, and right atrial
pressures;
– liver congestion and venous flow, respirophasic changes of the
vena cava;
– pathology to anticipate and to screen for in emergency echo-
cardiography (see chapter 2.27).
† Vascular indications:
– carotid intima-media thickness and plaques;
– stenosis of the carotid, vertebral, abdominal, and lower limb
arteries;
– thoracic and abdominal aortic diseases;
– venous insufficiency;
– anatomy of the pulmonary veins.
Skills
The ability to perform and interpret:
† trans-thoracic echocardiography;
† vascular ultrasound;
† trans-oesophageal echocardiography;
† stress-echocardiography.
Behaviours and attitudes
† Integration of echocardiographywith history taking, clinical exam-
ination, ECG (at rest and during exercise) as the baseline evalu-
ation of the cardiac patient by the general cardiologist;
† Recognitionof the strengths andweaknesses of echocardiography
in a clinical situation, and in relation to other imaging modalities.
The general cardiologist should be willing to refer to other
imaging modalities when necessary;
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† Interactive co-operation with sonographers and paramedical staff
for acquisition of the data.
2.3.3 Cardiac magnetic resonance
Knowledge
† Techniques
(a) basic CMR physics;
(b) image quality and artefacts;
(c) CMR safety and safety of medical devices in CMR;
(d) CMR contrast agents: indications and safety;
(e) CMR methodology
(i) cardiac anatomy (including dark and bright blood
techniques);
(ii) cardiac function (including cine andmyocardial tagging
methods);
(iii) tissue characterization (including contrast-enhanced
techniques);
(iv) CMR stress imaging (myocardial perfusion and dobu-
tamine stress CMR);
(v) blood flow assessment with flow-velocity encoded
CMR;
(vi) MR angiography.
† Indications
(a) ischaemic heart disease (IHD);
(b) diagnosis and management of chronic IHD;
(c) ischaemia testing with myocardial perfusion and dobutamine
stress CMR;
(d) viability assessment with late-gadolinium-enhanced (LGE)
CMR;
(e) coronary imaging;
(f) diagnosis and management of acute IHD;
(g) infarct size and area at risk in acute coronary syndromes
(ACS) with late-gadolinium enhancement and T2-weighted
CMR;
(h) LV and RV function post-myocardial infarction;
(i) microvascularobstruction and intramyocardial haemorrhage;
( j) myocardial disease
(i) diagnosis and prognostication in inherited cardiomy-
opathies;
(ii) diagnosis and prognostication in myocarditis;
(iii) cardiac involvement in systemic disease/secondary
cardiomyopathies;
(iv) diagnosis and prognostication in acute and chronic
heart failure;
(v) assessment of transplant cardiomyopathy;
(k) pericardial disease
(i) normal anatomy and diagnosis of pericardial disease;
(ii) assessment of functional effects of pericardial disease;
(l) vascular disease
(i) morphology and pathology of the thoracic and ab-
dominal aorta, including aneurysm and dissection;
(ii) morphology and pathology of the pulmonary vessels;
(iii) morphology and pathologyof the cervical arteries and
of the peripheral circulation;
(iv) morphology and pathology of the systemic veins;
(m) valvular disease
(i) assessment of valve morphology;
(ii) quantification of valve stenosis;
(iii) quantification of valve regurgitation;
(iv) LV and RV dimensions and function;
(n) cardiac and pericardial masses/tumours;
(o) congenital heart disease
(i) diagnosis and long-term follow-up;
(ii) quantification of shunt volumes;
(p) incidental (non-cardiovascular) findings.
Skills
The ability to:
† select appropriate indications for and avoid contraindications to
CMR examinations;
† supervise cardiovascular stress safely using pharmacological
techniques;
† display and interpret CMR images in the clinical context (level II
competence).
Behaviours and attitudes
† Continuing curiosity and willingness to refer for the rapidly evolv-
ing indications in the field of CMR;
† Cooperation with radiologists, paramedical and other medical
professionals.
2.3.4 Cardiac X-ray computed tomography
Knowledge
† Techniques
(a) test bolus acquisition and bolus chasing;
(b) prospective ECG-triggered axial, and retrospectively ECG-
gated spiral scan modes;
(c) cardiac X-ray CT without contrast enhancement
(i) coronary calcium score;
(d) cardiac X-ray CT with contrast enhancement
(i) coronary artery disease;
(ii) cardiac morphology;
(e) angiography of the great arteries and veins.
† Indications
(a) coronary artery disease
(i) coronary calcium score;
(ii) CT angiography of the coronary arteries to assess
degree of coronary stenosis;
(iii) bypass graft disease;
(iv) visualization of plaque characteristics;
(b) coronary anomalies;
(c) cardiac (non-coronary) pathology: congenital, traumatic, de-
generative, atherosclerotic (infarcts/LV aneurysms, etc.),
masses;
(d) interventional guidance: e.g. transcatheter valve implantation,
pulmonary vein isolation;
(e) ventricular function;
(f) prosthetic heart valve dysfunction
(i) quantification of opening and closing angles;
(ii) visualization of thrombus and pannus;
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(g) endocarditis of native heart valves and prosthetic heart valves
(i) visualization of valvular vegetations;
(ii) assessment of annular abscesses and mycotic aneur-
ysms and relationship to coronary arteries;
(h) congenital heart disease
(i) anatomy;
(ii) quantification of ventricular volumes and function;
(i) pericardial diseases
(i) including pericardial calcification;
( j) diseases of the great arteries and great veins (congenital
anomalies, aortic aneurysms, false aneurysms, aortic dissec-
tion, periaortic abscesses, aortic arch abnormalities;
(k) diseases of the cervical arteries and of the peripheral arteries.
Skills
The ability to:
† select appropriate indications for and avoid contraindications to
cardiac X-ray CT;
† display and interpret cardiac X-ray CT images in the clinical
context.
Behaviours and attitudes
† Cooperation with radiologists, paramedical, and other medical
professionals;
† Awareness of the side-effects of contrastmedia and recognition of
the risks of radiation to patient and personnel;
† Continuing curiosity and willingness to refer for the rapidly evolv-
ing indications in the field of X-ray computer tomography.
2.3.5 Nuclear techniques
Knowledge
† Techniques
(a) basic principles of radionuclide imaging as applied to the
cardiovascular system, including radio-isotopes, radio-
pharmaceuticals, gamma cameras, image acquisition, recon-
struction, display, and interpretation;
(b) single-photon emission computed tomography perfusion
scintigraphy (SPECT);
(c) gated SPECT (perfusion and LV function)
(i) tracers: 201Tl, 99mTc-sestamibi, or 99mTc-tetrofosmin;
(ii) modalities:
– rest imaging;
– stress imaging (exercise and pharmacological stress
with vasodilators and sympathomimetic agents);
– 2-day and 1-day protocols;
(d) positron emission tomography (PET): myocardial perfusion,
glucose metabolism, and inflammation imaging;
(e) hybrid techniques (PET-CT and SPECT-CT) for attenuation-
corrected imaging and for combined anatomical and function-
al imaging;
(f) radionuclide ventriculography using equilibrium planar and
SPECT imaging, and first-pass planar, phase, and amplitude
imaging of regional function;
(g) imaging of sympathetic innervation;
(h) imaging of pulmonary embolism, quantification of pulmonary
perfusion and right-to-left shunting;
(i) labelled leucocyte imaging for myocardial abscesses and
infection;
( j) imaging of myocardial sarcoidosis.
† Indications
(a) diagnosis of chest pain syndromes;
(b) managementof knownandsuspectedcoronaryarterydisease
including detection, localization, and quantification of myo-
cardial ischaemia and scar;
(c) assessment of prognosis in stable coronary artery disease, in
ACS and before non-cardiac surgery;
(d) assessment of LV dysfunction and heart failure, including
global and regional LV function, abnormalities of myocardial
motion and thickening, viability, stunning, hibernation, and in-
nervation;
(e) monitoring of LV function before and during cardiotoxic
chemotherapy;
(f) detection and quantification of left-to-right and right-to-left
shunting;
(g) detection of cardiac infection and inflammation.
Skills
The ability to:
† select appropriate indications for and avoid contraindications to
nuclear cardiology techniques;
† supervise cardiovascular stress testing using dynamic exercise and
pharmacological techniques;
† handle unsealed radiopharmaceutical sources in a manner that is
safe for oneself, patients and staff, and;
† display and interpret nuclear cardiology images (Level II compe-
tence).
Behaviours and attitudes
† Cooperation with referring colleagues and with nursing staff,
nuclearmedicinephysicians and technical andphysics professionals;
† Awareness of the side-effects of ionizing agents and recognition of
the risks of radiation to patient and personnel.
2.4 Invasive imaging: cardiac
catheterization and angiography
Objectives
† To perform and analyse:
– coronary and LV angiography;
– cardiac catheterization and haemodynamics.
† To obtain fully informed patient consent for the procedure.
Knowledge
† Principles of fluoroscopic imaging, radiation physics, exposure,
and safety regulations;
† Nephrotoxic effectsof contrast agents, their prevention, andman-
agement;
† Catheterization laboratory equipment (physiological monitoring,
transducers, blood gas analysers, power injector);
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† Radiological anatomy of the heart, aorta, large vessels, and coron-
ary arteries, as well as that of the femoral, radial, and brachial
arteries used for vascular access during catheterization;
† Collection of haemodynamic and oximetric data, and how to use
the measurements to calculate cardiac output, vascular resis-
tances, valve areas, and shunts;
† Interpretation of pressure waveforms, haemodynamic and
oximetric data;
† Techniques and sites of vascular access;
† Type of catheters used in cardiac catheterization and coronary
angiography;
† Trans-septal cardiac catheterization;
† Basic principles and indications for intracoronary ultrasound
(intravascular ultrasound, IVUS), Doppler, coronary artery pres-
sure measurements (FFR), and optical coherence tomography;
† Complications of cardiac catheterization and angiography and
their management.
Skills
The ability to:
† optimize use of the equipment to minimize exposure to
radiation in order to protect the patient and the catheteriza-
tion team, and to minimize the use of nephrotoxic contrast
agents;
† obtain arterial (femoral, radial, brachial) and venous access and
achieve haemostasis after catheterization;
† carry out left heart catheterization including coronary angiog-
raphy, ventriculography, aortography, and angiography of coron-
ary bypass grafts, including mammary artery grafts;
† carry out right heart catheterization in the catheterization labora-
tory and at the bedside, andmeasure cardiac output, intravascular
pressure, and oxygen saturation;
† manage life-threatening arrhythmias and other emergencies in the
catheter laboratory;
† assess normal and pathological coronary angiograms, ventriculo-
grams, aortograms, and pulmonary angiograms;
† interpret haemodynamic and oximetric data;
† use adjunctive pharmacological therapy safely and when
appropriate.
Behaviours and attitudes
† Assumption of responsibility for the appropriate ordering and
performance of invasive tests, while carefully balancing the risks
and benefits of these procedures. This implies avoidance of a
low threshold to proceed to invasive testing in low probability
cases;
† Cooperation with members of the Heart Team, nurses, techni-
cians, and other medical professionals;
† A consistent analytical approach to selecting the appropriate
treatment modality (medical, percutaneous, or surgical) based
on the clinical context as well as the data generated by cardiac
catheterization;
† Awareness of the side-effects of contrastmedia and recognition of
the risks of radiation to patient and personnel.
2.5 Genetics
Objectives
† Toassess andmanage patientswith inherited or familial cardiovas-
cular disease;
† To integrate genetics and epigenetics into the global evaluation of
risk in common cardiovascular disease.
Knowledge
† Integration of genetic knowledge in the evaluation of global risk
and common cardiovascular diseases;
† Incidence and prevalence of inherited cardiovascular disorders;
† Principles of
– Mendelian monogenic human diseases: autosomal dominant,
autosomal recessive and X-linked;
– mitochondrial patterns of inheritance;
– polygenic cardiovascular diseases.
† the major monogenic cardiovascular diseases, such as
– cardiomyopathies;
– familial aortopathies;
– familial arrhythmias;
– trisomies, in particular trisomy 21;
– familial dyslipidaemias.
Skills
The ability to:
† evaluate relevant family history and construct a family pedigree;
† counsel index cases and family members at risk on the probability
of being affected by a genetic cardiovascular disorder;
† recognize problems with pedigree interpretation such as incom-
plete penetrance, variable expressivity, and age-related patterns
of expressivity;
† manage the uncertainties associated with genetic testing;
† direct patients and families when appropriate to major centres
with a specialized interest in their particular disorder.
Behaviours and attitudes
† Cooperation with clinical geneticists and cardiologists specialized
in inherited heart diseases;
† A systematic approach to a family with a potentially inherited car-
diovascular disease;
† Adoption of appropriate counselling skills to explain, educate, and
inform patients fully of the nature of their disease;
† Commitment to improving the recognition and management of
familial cardiovascular disease.
2.6 Clinical pharmacology
Objectives
† To master the theory and practice of pharmacological treatment
of cardiovascular disorders.
Knowledge
† Classification, mode of action, and dosage of cardiovascular drugs
with emphasis on
– anti-arrhythmic drugs (including class I– IV);
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– anticoagulants, antiplatelet drugs, and fibrinolytics;
– beta- and alpha-adrenergic receptor blockers;
– calcium antagonists;
– diuretics;
– inhibitors of the renin–angiotensin–aldosterone system;
– inotropic drugs;
– lipid-lowering drugs;
– other anti-ischaemic drugs (nitrates, potassium channel
blockers, haemodynamically neutral antianginal agents);
– sinus node inhibitors;
– vasodilators.
† Pharmacokinetics, pharmacodynamics, pharmacogenetics, indica-
tions, contraindications, interactions, adverse effects, and toxicity
of cardiovascular drugs;
† Individually tailored choice of drug or combination of drugs
according to the patient’s age, profile, co-morbidities, genetic
background, and ethnicity;
† Cardiovascular side-effects of non-cardiovascular drugs;
† Interpretation of diagnostic tests to assess drug efficacy and safety
(laboratory tests, ECG, haemodynamic monitoring, and echo);
† Methodology of research and statistics;
† Evidence-based medicine as the basis for pharmacotherapy.
Skills
The ability to:
† take a full and accurate history of a patient’s medication regimen,
including over the counter medicines and alternative remedies;
† assess the risks and benefits of prescribing an individualized drug
treatment regimen for a given cardiovascular condition;
† monitor the desired effects and side-effects of a patient’s drug
therapy and make appropriate modifications to the treatment
regimen;
† prevent, recognize, andmanagepossible drug interactions (includ-
ing treatments of concomitant diseases);
† evaluate the design and results of published clinical trials.
Behaviours and attitudes
† Communication with hospital and community pharmacists as
equal partners in healthcare;
† Incorporation of the principles of evidence-based therapy and
current guidelines into clinical pharmacology;
† Communication with patients and their family members to
improve treatment compliance and to ensure early recognition
of possible adverse effects;
† Consideration of the cost-effectiveness and feasibility of the
prescribed treatment regimen.
2.7 Cardiovascular prevention
2.7.1 Cardiovascular risk factors, assessment, and
management
Objectives14
† To assess and manage patients with risk factors for cardiovascular
disease;
† To understand the mode of action of different prevention
methods;
† To describe cardiovascular disease and risk factors in the local
community;
† To contribute to the global efforts in reducing cardiovascular
morbidity and mortality by communicating the prevention
message to the public;
† To approach prevention in a holistic way, understanding the
potentiation of cardiovascular risk by clustering of risk factors.
Hypertension18
See Chapter 2.7.2.
Dyslipidaemia19
† To diagnose and treat different forms of dyslipidaemia;
† To assess cardiac and extra-cardiac complications of dyslipidaemia.
Diabetes20
† To diagnose diabetes type I and II and its cardiovascular
complications;
† To have a knowledge of diabetes treatment.
Lifestyle. Hard return lifestyle should be given the same weight as
major risk factors:
† To be aware of the importance of lifestyle (smoking, diet, and
exercise) in cardiovascular disease and its prevention;
† To implement methods to correct unhealthy lifestyles.
Knowledge
† Epidemiology of cardiovascular disease in the local community:
incidence, prevalence, survival;
† Risk factors in the local community;
† Risk assessment in primary prevention: multifactorial risk inter-
action and use of risk scoring charts;
† The impact of lifestyle on people at risk of, and patients with,
cardiovascular disease;
† The potential of lifestyle changes to prevent and ameliorate car-
diovascular disease: diet and nutrition, toxic habits (smoking,
alcohol and others), physical activity;
† Emerging risk factors (social, economic, stress, depression, and
personality type);
† Treatment/prevention strategies for major risk factors and changes
in lifestyle, including corresponding pharmacologic therapies;
† The comprehensive approach required for multiple risk factors;
† Patient compliance.
Hypertension
See Chapter 2.7.2.
Dyslipidaemia
† Epidemiology, aetiology, and pathophysiology of dyslipidaemia;
† Complications of dyslipidaemia;
† Diagnosis and assessment of dyslipidaemia;
† Management of dyslipidaemia, including pharmacologic and non-
pharmacologic therapies;
† Detection and management of side-effects of lipid-lowering agents;
† Management of dyslipidaemia in patients with reduced tolerance
to lipid-lowering agents.
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Diabetes mellitus
† Epidemiology, aetiology, and pathophysiology of diabetes;
† Consequences of diabetes;
† Diagnosis and assessment of diabetes: clinical symptoms and
laboratory tests;
† Basic management of diabetes, including pharmacological and
non-pharmacological therapies;
† Appreciationof the continuum from impairedglucosemetabolism
to overt diabetes that ultimately may become insulin requiring.
Lifestyle.
† Smoking:
– risk associated with smoking;
– benefits associated with stopping smoking;
– treatment options for smoking cessation, including drugs.
† Diet:
– the effect of different types of diet on metabolic profile and
clinical outcomes;
– components of diet associated with a higher rate of athero-
sclerosis and cardiovascular disease;
– protective components of diet.
† Exercise:
– risks associated with a sedentary lifestyle;
– benefits associated with exercise;
– evaluation of physical activity;
– physical activity regimens for individuals in primary and second-
ary prevention.
Skills
The ability to:
† obtain a relevant historyandperformanappropriateclinical exam-
ination;
† evaluate cardiovascular risk and assess global cardiovascular risk at
the individual level (including HeartSCORE)21;
† evaluate cardiovascular risk atpopulation level (mortality,morbid-
ity, disability);
† evaluate the benefit of prevention at individual and population
levels;
† manage risk factors appropriately, including pharmacological and
non-pharmacological therapies;
† communicate their importance to patients, their families, and the
wider community, including smoking cessation, diet, and exercise;
† communicate the importance of patient compliance and
behaviour;
† motivatepatients and families to change lifestyles andbecompliant
with prescriptions/recommendations;
† monitor patient compliance and behaviour;
† evaluate the benefit of risk factor intervention for the individual
patient.
Behaviours and attitudes
† Non-judgemental attitude to patients regarding their lifestyle
(e.g. smoking, diet, etc.);
† Exemplify appropriate lifestyle in personal behaviour;
† Team working with other physicians, including general practi-
tioners, diabetologists, nephrologists, and elderly care physicians
for the management of specific risk factors;
† Teamworkingwith all professionalswith a role in primary and sec-
ondary prevention (nurses, dieticians, teachers, and politicians).
2.7.2 Arterial hypertension
Objectives18
† To identify, assess, and manage patients with elevated blood
pressure (BP);
† To integrate arterial hypertension in the evaluation of global
cardiovascular risk;
† To identify arterial hypertension as a risk factor for ischaemic
heart disease, heart failure, cerebrovascular disease, peripheral
artery disease renal failure, atrial fibrillation, and cognitive
dysfunction.
Knowledge
† Definition and classification of hypertension;
† Pathophysiology of hypertension: contribution of cardiac output,
peripheral artery resistance, and age-related stiffening of the great
arteries in the genesis of primary hypertension;
† Central BP and its relation to brachial BP;
† Aetiology and pathophysiology of secondary hypertension
(renovascular, renal, hormonal, oestrogen induced, and other
causes);
† Interaction between BP regulation and sleep apnoea;
† White-coat hypertension, masked hypertension and implications
for measurement of BP and therapeutic decision-making;
† Factors influencing prognosis of hypertension;
† Target organ damage and complications of hypertension for the
brain, the kidneys, and the great arteries;
† Lifestyle measures for prevention and treatment of hypertension;
† Pharmacological properties, indications and side-effects of the
various classes of antihypertensive drugs;
† Individually tailoredchoiceof antihypertensivedrugorcombination
of drugs according to the patient’s age, profile, co-morbidities,
genetic background, and ethnicity;
† Interventional techniques for BP control (e.g. renal artery stenosis
dilatation, renal artery denervation);
† Targets for BP lowering;
† Definition and management of refractory hypertension;
† Definition and management of malignant hypertension.
Skills
The ability to:
† measure and interpret BP obtained with manual and automatic
office devices and ambulatory and home BP monitors;
† evaluate a patient with elevated BP, including comprehensive
blood testing, screening for diabetes, the electrocardiogram,
echocardiography and vascular ultrasound, central BP assessment,
renal function, proteinuria and microalbuminuria, ABI, and
fundoscopy;
† manage elevated BP non-pharmacologically and pharmacologically;
† reduce global cardiovascular risk in patients with hypertension,
including the use of pharmacological therapy;
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† manage hypertensive emergencies.
Behaviours and attitudes
† Team working with general practitioners and other medical
specialists in the management of patients with hypertension; in
particular, elderly patients, diabetes patients, patients with
chronic kidney disease, and patients with cerebrovascular disease;
† Appreciationof the systemic nature of hypertension and its conse-
quences for various vascular beds;
† Awareness of hypertension as major risk factor for cardiovascular
diseases;
† Appreciation of and safeguarding against the potential for both
under-treatment and over-treatment of patients with high BP;
† Motivation of the patient to maintain long-term compliance with
antihypertensive therapy;
† Active participation in hypertension prevention, detection, and
treatment programmes in the community.
2.8 Acute coronary syndromes
Objectives2,8,9,15 (see also Chapter 27: Acute cardiovascular care)
† To perform specialist assessment and treatment of patients with
ACS including
– STE-ACS (ST-segment elevation ACS) or STEMI (ST-segment
elevation myocardial infarction);9
– NSTE-ACS (non-ST-segment elevation ACS) or NSTEMI
(non-ST-segment elevation myocardial infarction);8
– unstable angina.
Knowledge
† Diagnostic criteria for ACS and myocardial infarction;
† Classification of myocardial infarction15;
† Pathophysiology of ACS, including plaque rupture or erosion,
thrombosis, vasospasm, immunity (innate and acquired) and cell
necrosis. Impact at the level of epicardial coronary arteries,
smaller arteries, the micro-circulation, and the myocardium;
† Knowledge of non-atherosclerotic causes of ACS (e.g. variant
angina, coronarydissection, tako tsubocardiomyopathy, coronary
embolism);
† Events that precipitate ACS;
† Dominant clinical features of ACS;
† Diagnostic process in patients with chest pain with suspicion of
unstable angina, NSTE-ACS or STE-ACS;
† Diagnostic techniques including ECG, troponin and other
biomarkers, echocardiography and other imaging modalities;
† Risk scores in patients with ACS;
† Monitoring (ECG and hemodynamic monitoring);
† Treatment of ACS: pre- and early hospital pharmacological
therapy. Indications for interventional therapy based on clinical
judgement and available risk scores;
† Properties, effects, indications, contraindications, and secondary
effects of analgesics, anti-ischaemic drugs, anticoagulants,
fibrinolytics, platelet inhibitors, statins, and other drugs for sec-
ondary prevention - use and complications of antithrombotic
drugs in combination;
† PCI techniques, balloon techniques, stents;
† Role and treatment of co-morbidities;
† Early and late complications of ACS and their treatment.
Skills
The ability to:
† take a relevant history and perform an appropriate clinical
examination;
† appreciate the role of risk factors, the clinical characteristics of
coronary occlusion, and the subsequent clinical course;
† repeated biomarkers measurements and their kinetics
interpretation;
† interpret ECG and imaging techniques to detect and localize
ischaemia and/or infarction;
† use algorithms for diagnosis;
† obtain informed consent for invasive procedures;
† monitor patients with ACS;
† prescribe appropriate pharmacological treatment including analge-
sics, anti-ischaemic drugs, anticoagulants, fibrinolytics, platelet
inhibitors, statins, and other drugs for secondary prevention;
† use a risk score to evaluate prognosis and select patients for early
or delayed coronary angiography and revascularization;
† diagnose and treat complications during the acute phase of ACS.
Behaviours and attitudes
† Teamworkingwith other specialists, includingmedics/paramedics
in ambulances and mobile coronary care units, nurses, and physi-
cians in the emergency department, intensive care unit or cardiac
monitoring unit and catheterization laboratory. This includes
the Heart Team (cardiologists, interventional cardiologists,
anaesthetists, and cardiac surgeons) for decisions on urgent
revascularization;
† Appreciation of the urgency of making decisions on patients with
ACS, from the time of onset of symptoms until therapy is adminis-
tered with special emphasis on minimizing time to reperfusion;
† Appreciation of the distress that unexpected and serious illness
causes both to patients and to their relatives;
† Willingness to play an appropriate role in a hospital network
for optimal management of patients presenting with ACS, and
transferring patients quickly;
† Willingness to contribute to improving public awareness of the
significance of chest pain and to encourage early presentation.
2.9 Chronic ischaemic heart disease
Objectives2,22
† To perform specialist assessment and treatment of patients with
chronic IHD;
† To interpret the results of diagnostic procedures to evaluate
ischaemia, ventricular function and complications of chronic
IHD; and
† To select and apply appropriate therapies for ischemia, secondary
prevention and complications of chronic IHD.
Knowledge
† Epidemiology of chronic IHD and its risk factors;
† Molecular and cellular biology of IHD;
† Coronary physiology;
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† Pathophysiology of ischaemia: plaque formation, clotting, innate
and acquired immunological mechanisms, vasospasm;
† Effects of myocardial ischaemia on the myocardium, including
stunning, hibernation, and viability;
† Events that precipitate an angina attack;
† Prognosis of chronic IHD;
† Clinical assessment of knownor suspected chronic IHD, including
differential diagnosis of chest pain and other symptoms and signs.
Non-invasive test interpretation based on Bayes’ law;
† Indications for, and information derived from, diagnostic proce-
dures including ECG, stress test in its different modalities (with
or without imaging, exercise, and stress drugs) and coronary
angiography;
† Exercise physiology;
† Management of chronic IHD, including lifestyle measures and
pharmacological management;
† Indications for coronary revascularization including PCI, stenting,
and CABG;2
† Participants in, and role of, the Heart Team;
† Knowledge of alternative interventions for chronic refractory
angina (e.g. external counterpulsation, spinal denervation, spinal
cord stimulation).
Skills
The ability to:
† take a relevant history and perform an appropriate clinical
examination;
† select, use, and interpretnon-invasive and invasivediagnostic tools
for the evaluation of ischaemia, viability, LV structure and function,
and coronary anatomy;
† interpret the ECG to detect ischaemia and identify arrhythmias;
† manage life-threatening arrhythmias, ischaemia, or other emer-
gency situations during diagnostic tests;
† risk-stratify individual patients and select an appropriate manage-
ment strategy;
† identify and treat risk factors for chronic IHD; and
† use appropriate therapies for secondary prevention and treat-
ment of ischaemia, and select patients for revascularization.
Behaviours and attitudes
† Commitment to working with the Heart Team (interventional
cardiologists, anaesthetists, and cardiac surgeons) and, where
appropriate, with input from general practitioners, elderly
care physicians, and intensivists to reach a decision on
revascularization;
† In the absence of on-site cardiac surgery, a consistent approach to
applicationof agreed evidence-basedprotocols, andwillingness to
collaborate with off-site expert interventional cardiologists and
cardiac surgeons.
2.10 Myocardial diseases
Objectives
† To perform a comprehensive assessment and treatment of
patients with cardiomyopathy and myocarditis.
Knowledge
Cardiomyopathy
† Epidemiologyandclassificationof dilated, hypertrophic,23 restrict-
ive, arrhythmogenic, and unclassified cardiomyopathies;
† Pathophysiology including genetics, diseases causing cardiomyop-
athies, clinical features, and diagnostic criteria of cardiomyop-
athies;
† Medical and invasive (surgical, electrophysiological, and interven-
tional) management of cardiomyopathies: indications, contraindi-
cations, and possible adverse effects;
† Prognostic factors.
Myocarditis
† Myocarditis as an inflammatorydisease, its causes, and its consecu-
tive phases (acute, sub-acute, chronic);
† Clinical features, imaging techniques (in particularCMR), pathology,
and diagnostic criteria for infective and non-infective myocarditis;
† Treatment of patients with myocarditis and its complications.
Skills
The ability to:
† take a relevant history, family history, and perform an appropriate
clinical examination;
† interpret diagnostic data (ECG, ambulatory ECG, echo, exercise
testing, chest X-ray, cardiac catheterization, coronary angiog-
raphy, magnetic resonance and radionuclide imaging, endomyo-
cardial biopsy, genetic report);
† select appropriate treatment and support modalities (medical,
interventional, surgical, ICD/CRT, assist devices, balloon pumping,
or other treatment);
† assess individual prognosis in relation to the need for transplant-
ation;
† evaluate patients for endomyocardial biopsy recognizing the
diagnostic yield and potential risk of the procedure.24
Behaviours and attitudes
† Alertness to the possibility of infiltrative cardiomyopathy in the
presence of unexplained hypertrophy or heart failure;
† Cooperation with medical professionals in other specialties
(immunology, bacteriology, genetics, cardiac surgery, interven-
tional cardiology, and imaging) for timely differential diagnosis of
myocardial disease and further treatment;
† Sensitivity in counselling patients with cardiomyopathies and
their relatives about the risks of transmission and the value and
limitations of genetic testing and phenotypic screening.
2.11 Pericardial diseases
Objectives25
† To perform specialist assessment and treatment of patients with
pericardial diseases.
Knowledge
† Classification and definition:
– acute pericarditis;
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– relapsing pericarditis;
– chronic pericarditis;
– pericardial effusion and cardiac tamponade;
– constrictive and effusive-constrictive pericarditis.
† Epidemiology, pathophysiology, and aetiology of pericarditis,
including infective, inflammatory, and neoplastic disorders;
† Relevant investigations: non-invasive and invasive, including
interpretation of laboratory findings;
† Differential diagnosis of constrictive pericarditis from restrictive
cardiomyopathy;
† Indications for pericardiocentesis;
† Drug therapy for controlling pericardial inflammation;
† Management of pericarditis and its complications;
† The transient nature of constrictive physiology in some cases.
Skills
The ability to:
† take a relevant history and perform an appropriate clinical
examination;
† recognize the ECG abnormalities in acute pericarditis;
† use and interpret echocardiography as the gold standard for initial
diagnosis and follow-up;
† select and use additional non-invasive imaging modalities (CMR,
X-ray CT, PET) to diagnose pericardial disease;
† perform and interpret invasive pressure measurements to
diagnose pericardial disease;
† differentiate pericarditis from myocardial ischaemia;
† perform pericardiocentesis.
Behaviours and attitudes
† Alertness to pericardial diseases within the differential diagnosis
of a patient presenting with cardiovascular symptoms and signs;
† Awareness and adoption of the different diagnostic and
therapeutic strategies required for each individual case;
† Teamworkingwith intensivists, anaesthetists, radiologists, cardiac
surgeons, and oncologists.
2.12 Oncology and the heart
Objectives26,27
† To develop knowledge of the manifestations of primary, benign
and malignant, and metastatic cardiac tumours;
† To evaluate cardiovascular effects of malignancies and cancer
therapies (chemotherapy, radiotherapy, and cancer surgery);
† Toparticipate in themanagement of patientswith tumours involv-
ing the heart and with cardiovascular complications associated
with the treatment of non-cardiac malignancies.
Knowledge
† Symptoms and signs of cardiac tumours, including systemic and
embolic manifestations;
† Classification, diagnosis, and therapy of primary and metastatic
cardiac tumours;
† Effectsof tumoursoncoagulationand theoccurrenceof thrombo-
embolism;
† Obstruction to blood flow induced by proliferative processes
(e.g. vena cava syndrome, atrial myxoma, pulmonary artery
compression);
† Effects of thoracic radiotherapy on the pericardium, myocardium,
conducting system, and coronary arteries;
† Cardiac toxicity associated with cancer therapy: e.g. anthracy-
clines, trastuzumab, and protein kinase targeted therapeutics;
† Other adverse effects of chemotherapeutic drugs: myocardial
ischaemia; thrombosis, and embolism; altered BP; rhythm and
conduction disturbances: bradycardia and heart block, tachycar-
dia, arrhythmias;
† Complications of permanent venous access devices;
† Strategies for preventing adverse effects of chemotherapeutic
drugs (e.g. statins).
Skills
The ability to:
† use appropriate imaging modalities for diagnosing primary and
metastatic tumours and for differentiating tumours from non-
neoplastic cardiacmasses such as thrombi or vegetations, or aber-
rant variants of normal structures;
† evaluate the cardiovascular system of patients prior to cancer
therapy;
† evaluate the cardiovascular system of patients during and after
cancer therapy;
† follow-up and treat oncological patients with cardiovascular
complications.
Behaviours and attitudes
† Teamworkingwith general practitioners, oncologists, oncological
nurses, radiologists, and surgeons;
† Willingness to refer the oncological patient for invasive cardiac
evaluation and cardiac biopsy when indicated;
† Empathic and supportive approach towards the psychologically
vulnerable oncological patient.
2.13 Congenital heart disease in adult
patients
Objectives28
† To evaluate andmanage adolescent and adult patients with simple
congenital heart defects (grown-up congenital heart disease,
GUCH) including those who have undergone cardiac surgery;
† To recognize complex conditions which require referral to a spe-
cialist GUCH centre;
† To monitor complex patients in collaboration with a specialist
GUCH centre;
† To assess and provide immediate management of emergencies in
patients with congenital heart disease.
Knowledge
† Physiology of the foetal and transitional circulations;
† Aetiologyof congenital heart disease, including the developmental
anatomy of the heart and vasculature;
† Commonly associated genetic syndromes;
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† Anatomyof theheart, veins, andgreat vessels; theirmajorcongeni-
tal malformations and the principles of nomenclature;
† Pathophysiology, natural history, and complications of:
– valve and outflow tract lesions;
– septal defects;
– patent ductus arteriosus;
– Eisenmenger syndrome;
– coarctation of the aorta;
– Ebsteins’s anomaly;
– aortic and pulmonary artery malformations;
– venous anomalies;
– transposition of the great arteries (complete and congenitally
corrected);
– tetralogy of Fallot;
– functionally univentricular hearts and the Fontan circulation;
– congenital malformations of coronary arteries;
– cyanotic congenital heart disease and secondary erythrocytosis;
– pulmonary hypertension in congenital heart disease.
† Arrhythmias and conduction disturbances;
† Pathophysiology, natural history, and complications of palliative
and corrective surgery and interventions;
† Physical signs of congenital heart disease and its complications
† Diagnostic techniques;
† Principles of medical, interventional, and surgical management;
† Prevention of infective endocarditis (IE);
† Hazards of pregnancy, contraception, intercurrent illness, and
non-cardiac surgery in patients with congenital heart disease.
Skills
The ability to:
† take a relevant history and perform an appropriate clinical
examination;
† select imaging techniques and, where appropriate, invasive proce-
dures for diagnosis;
† providemonitoring and follow-up, where appropriate in collabor-
ation with a specialist GUCH centre, and lifestyle advice;
† manage the patient with pulmonary hypertension and with
secondary erythrocytosis.
Behaviours and attitudes
† Acceptance of the role of GUCH specialist teams in the manage-
ment of patients with complex malformations and complications;
† Appreciation of the importance of long-term surveillance of
patients with congenital heart defects;
† Commitment tomulti-disciplinary management, including genetic
counselling; and
† Understanding and empathy in connection with the social and
emotional difficulties encountered by adult patients with congeni-
tal heart disease and their relatives.
2.14 Pregnancy and heart disease
Objective29
† Toperformspecialist cardiacevaluation,management, and follow-
up of women with known or suspected heart disease before,
during, and after pregnancy.
Knowledge
† Physiological, haemodynamic, haemostatic, and metabolic altera-
tions during pregnancy
– thenormal echocardiogramduringpregnancyandpuerperium.
† Complications during pregnancy and puerperium in women
without known cardiovascular disease:
– thrombo-embolism;
– hypertensive disorders (pre-/eclampsia);
– ischaemic coronary events including ACS;
– spontaneous coronary dissection, aortic, or vascular dissection;
– arrhythmia;
– peripartum cardiomyopathy.
† For patients with knownor suspected cardiovascular diseasewho
are contemplating pregnancy are pregnant or post-partum:
– conditions for which pregnancy is contra-indicated (and those
which justify early termination);
– indications for genetic counselling;
– conditions associated with a high risk of pregnancy-related
cardiac complications for which intervention before consider-
ing pregnancy is appropriate;
– appropriate follow-up during pregnancy and post-partum;
– conditions requiring medical therapy during pregnancy;
– situations inwhich cardiac interventionmay be required during
pregnancy;
– management of anticoagulant therapy,with special attention to
patients with valve prostheses;
– endocarditis during pregnancy;
– modalities of delivery and their major indications.
† Modalities for foetal assessment and diagnosis of genetic malfor-
mations;
† Cardiovascular pharmacology during pregnancy and lactation;
† Efficacy, risks, and contraindications associated with the various
contraceptive methods according to the nature of the underlying
heart disease.
Skills
The ability to:
† take a relevant history and perform an appropriate clinical
examination;
† recognize the symptoms and signs associated with the haemo-
dynamic changes associated with pregnancy;
† differentiate physiological from pathological dyspnoea during
pregnancy;
† assess the cardiac risk of pregnancy on the basis of clinical
evaluation and the interpretation of diagnostic procedures;
† recognize the necessity and undertake or refer for preventive
cardiac intervention where appropriate;
† diagnose andmanage themost frequent or serious cardiovascular
complications during pregnancy;
† perform diagnostic procedures when indicated during pregnancy
and post-partum;
† exercise testing;
† echocardiography and vascular ultrasound;
† other imaging techniques, paying due regard to the hazards
of radiation exposure to the foetus;
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† select drug therapies that can be used safely during pregnancy and
breast feeding;
† manage pregnant patients who require ongoing anticoagulation
for prophylaxis or treatment of thrombotic complications. This
shouldbedone in closecollaborationwith a tertiaryexpert centre;
† evaluate the foetal andmaternal riskof different cardiac interven-
tions;
† evaluate the cardiac condition after pregnancy;
† assess the cardiac risk of subsequent pregnancies.
Behaviours and attitudes
† Recognition of the importance of pre-pregnancy counselling and
education for women with heart disease and their partners;
† Cooperationwith gynaecologists and obstetricians with regard to
recommendations on contraception;
† Cooperation during pregnancy, peri-partum, and post-partum
with a multi-disciplinary team of gynaecologists, obstetricians,
anaesthetists, neo-natologists, and midwives;
† Recognition of the importance of patient education on the
symptoms of poor cardiac tolerance;
† Alertness to the risk of worsening cardiac status during the early
post-partum period and the importance of communication with
obstetricians and midwives.
2.15 Valvular heart disease
Objectives4
† To perform a specialist assessment and treatment of patients
valvular heart disease (VHD):
– diseases of native aortic, mitral, tricuspid and pulmonary valves
and their combinations;
– surgically or percutaneously repaired cardiac valves;
– surgically or percutaneously implanted valvular prostheses.
Knowledge
† Haemodynamics of VHD;
† Pathophysiology: effects of VHDon the heart and on the circulation;
† Natural history of VHD;
† Strengths and limitations of diagnostic techniques, in particular
echocardiography, and the value of additional procedures such
as fluoroscopy, X-ray CT, magnetic resonance imaging, and inva-
sive haemodynamic assessment;
† Values and limitations of different risk scores applied to VHD;
† Indications, benefits, and risks ofmedical therapy, surgical and per-
cutaneous interventions for VHD;
† Indications for and management of anticoagulant therapy;
† Role of concomitant coronary heart disease in VHDand its impact
on surgical management;
† Follow-up and medical management of native VHD;
† Follow-up and management of repaired valves, bioprostheses,
mechanical prosthetic valves, and percutaneously repaired and
implanted valves.
Skills
The ability to:
† take a relevant history and perform an appropriate clinical
examination;
† use appropriate non-invasive or invasive diagnostic techniques;
† interpret results of diagnostic procedures;
† decidewhether andwhen surgeryor percutaneous intervention is
indicated;
† assess risks and benefits of valvular interventions according to
patient characteristics and the type of intervention; and
† recognize and manage the complications that may occur in
patients with prosthetic valves or after valvular interventions.
Behaviours and attitudes
† Recognition of the importance of patient education with respect
to the natural history of VHD, management of anticoagulation,
and prophylaxis of bacterial endocarditis;
† Provision of balanced, readily understood, and appropriate infor-
mation to the patient on the risks and benefits of different valvular
interventions (repair/replacement);
† Explanation of the pros and cons of each type of prosthesis (bio-
logical and mechanical);
† Recognition of the importance of patient compliance;
† Commitment to work in a Heart Team with cardiovascular sur-
geons, anaesthetists, interventional cardiologists, and radiologists;
† Understanding of the appropriate frequency of follow-up with
specific reference to the clinical condition after surgery or
intervention.
2.16 Infective endocarditis
Objectives30
Endocarditis
† To assess, diagnose, and treat patients with Infective endocarditis
(IE) of native and prosthetic valves, prosthetic material, and
indwelling devices such as pacemakers, ICDs, and catheters.
Prevention
† To perform preventive strategies in at-risk patients, including the
prevention of nosocomial infections.
Knowledge
Endocarditis
† Epidemiology of endocarditis in relation to the ageing population,
to surgical interventions, and to the increasing prevalence of
prosthetic cardiac implants;
† Clinical features of different formsof endocarditis, including native
valve, right heart, prosthetic valve (early and late after surgery),
catheter and cardiac device-related infection (pacemaker, ICD);
† Classification of IE according to the mode of acquisition
(a) healthcare associated
(i) nosocomial;
(ii) non-nosocomial;
(b) community-acquired;
(c) intravenous drug abuse-related.
† Active or recurrent (relapse, re-infection);
† Pathology, pathophysiology, and microbiology;
† Symptoms and signs;
† Laboratory investigations including microbiological results and
their limitations;
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† Cardiac imaging including trans-oesophageal echocardiography,
magnetic resonance imaging, and PET computer tomography;
† Medical management and monitoring;
† Surgical management;
† Complications and their management.
Prevention
† Measures for minimizing or preventing bacteraemia;
† Cardiac conditions at highest risk for IE;
† Procedures considered high risk for the development of IE;
† Indications for antibiotic prophylaxis.
Skills
Endocarditis
The ability to:
† take a relevant history and perform an appropriate clinical
examination;
† select, use, and interpret echocardiographic approaches including
trans-oesophageal echocardiography;
† perform an immediate prognostic evaluation on admission;
† select an appropriate antibiotic regimen;
† manage and monitor a patient with IE;
† organize immediate and long-term follow-up;
† determine the need for and timing of surgery;
† manage complications.
Prevention
The ability to:
† ensure good oral health in patients at risk;
† implement antibiotic prophylaxis for the prevention of IE in
patients at high risk.
Behaviours and attitudes
† Commitment to working in a Heart Team with cardiac surgeons,
intensivists, infectious diseases specialists, and microbiologists for
diagnosis and management of IE;
† Recognition of the importance of patient and physician education
on prophylaxis and the prevention of nosocomial infections;
† Recognition of the importance of patient compliance in prevention;
† Consistent provision of information to patients at risk and practi-
tioners on the importance of prevention and the initial symptoms
of endocarditis.
2.17 Heart failure
Objectives7
† To recognize the impact of heart failure on morbidity and
mortality in the individual patient and in the population at large;
† To recognize heart failure and the different underlying causes;
† To perform specialist assessment and treatment of patients with
heart failure;
† To work with patients and their families’ primary care physicians,
sub-specialists, nurses, and other healthcare professionals; and
† To organize structured follow-up of patients after discharge from
hospital.
Knowledge
† Definition of heart failure;
† Pathophysiology of heart failure, systolic and diastolic dysfunction;
† Epidemiology and prognosis of heart failure with reduced and
preserved ejection fraction (HFREF and HFPEF);
† Precipitating factors of heart failure;
† aHA stages of heart failure (A-D), Weber-Janicki classes of heart
failure (peak VO2);
† International classification of functional limitation (NYHA class);
† Diagnostic procedures in the patient with known or suspected
HF including chest X-ray, echo-Doppler,31 natriuretic peptides,
cardiac X-ray CT and CMR, stress (including cardiopulmonary
exercise) testing, cardiac catheterization;
† Importance of co-morbidities for prognosis of HF, including
anaemia, renal impairment, depression, chronic obstructive pul-
monary disease, and cachexia;
† Prognostic evaluation of the heart failure patient;
† Medical management of acute and chronic HF;
† Device management of HF: cardiac resynchronization therapy.5,32
See also Chapter 2.20.
(a) Implantable cardioverter defibrillator (ICD)
(i) To select patients with an indication for an ICD;
(ii) To have a good understanding of ICD implantation,
device programming, and follow-up.
(b) Cardiac resynchronization therapy
(i) To select patients with an indication for CRT;
(ii) To have a good understanding of CRT implantation,
device programming; and follow-up.
† Advanced supportive therapy, including (non-invasive) ventilation,
ultrafiltration, and dialysis techniques;
† Interventional therapies such as conservative surgical and percu-
taneous procedures (including coronary revascularization and
percutaneous interventions on the mitral valve), assist devices,
artifical heart, and transplantation;
† Impact of coronary revascularization on the prognosis of HF
patients;
† The role of exercise training programmes in HF patients;
† Complications of HF;
† Impact of optimized follow-up on prognosis of patients with HF
(LV filling pressure monitoring, serial biomarkers determinations,
biomarkers-guided therapy, telemedicine);
† Principles of palliative care.
Skills
The ability to:
† detect warning signs, symptoms, and clinical signs of HF;
† select andusediagnostic techniques todifferentiate theunderlying
causes and precipitating factors of HF and to evaluate volume
status, cardiac function, and pulmonary pressures;
† educate patients and their relatives about self-care management,
and the importance of adherence to therapy;
† manage acute HF medically. See Chapter 2.27;
† manage chronic HF medically;
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† deliver lifestyle advice and a home-based treatment strategy to
patients;
† risk-stratify HF patients and select appropriate drug and other
therapies;
† evaluate HF patients during follow-up and continuously adjust the
treatment plan as appropriate.
Behaviours and attitudes
† Recognition of the importance of patient education with respect
to the importanceof lifestyle, exercise andweight loss, compliance
with dietary measures, fluid restriction (when appropriate), and
medication;
† Appreciation of the importance of rehabilitation and continued
physical training;
† Commitment to work in a team with nurse practitioners or phys-
ician assistants;
† Commitment towork in teamwith electrophysiologists and heart
failure specialists for the follow-up of patientswith device therapy;
† Recognition of the importance of supportive and palliative care in
patients with advanced heart failure.
2.18 Pulmonary arterial hypertension
Objectives33
† To diagnose pulmonary hypertension;
† To distinguish between the different causes of pulmonary
hypertension;
† To provide optimal management for patients with pulmonary
hypertension.
Knowledge
† Pulmonary hypertension and its pathophysiological classification;
† Clinical classification and its rationale;
† Epidemiologyof pulmonary hypertension, in particular pulmonary
arterial hypertension (incidence, prevalence, aetiology, genetics,
high-risk groups);
† Pathology and pathophysiology of different types of pulmonary
hypertension;
† Clinical features of different aetiologies of pulmonary
hypertension;
† Diagnostic criteria of pulmonary hypertension;
† Prognostic markers;
† Medical, surgical, and interventional management of pulmonary
hypertension, including indications, contraindications, and adverse
effects. Specifically disease targeted therapies and indications for
pulmonary endarterectomy;
† Complicationsof pulmonary hypertension and theirmanagement.
Skills
The ability to:
† take a relevant history and perform an appropriate clinical
examination;
† recognize clinical signs of pulmonary hypertension and its
associated diseases;
† differentiate between pulmonary hypertension andother diseases
with similar symptoms;
† interpret investigations including ECG, echocardiography, lung
function tests, arterial blood gases, serum cardiac biomarkers,
6-min walk testing, CPX, ventilation–perfusion scanning, X-ray
CT pulmonary angiography, CMR imaging, liver ultrasound,
selective pulmonary angiography and haemodynamics derived
from cardiac catheterization;
† set treatment goals and prescribe appropriate medical or invasive
(surgical or interventional) management;
† provide advice on family planning;
† provide or refer for genetic counselling families affected by familial
PAH;
† evaluate prognostic markers;
† initiate end-of-life care when appropriate;
† undertake screening for high-risk patients.
Behaviours and attitudes
† Cooperation with a multi-disciplinary team in delivering chronic
disease management that may include general practitioners,
respiratory physicians, internal medicine practitioners, surgeons,
nurses, community healthcare workers, rehabilitation teams, and
other professionals;
† Acknowledgement of the importance of expert centres (when
available) and being prepared to refer patients when appropriate;
† Collaboration with patient associations.
2.19 Physical activity and sport in primary
and secondary prevention
2.19.1 Sports cardiology
Objectives14
† To conduct strategies to implement healthy lifestyle, in particular
physical and sports activities in the general population (primary
prevention);
† To evaluate cardiovascular risk and exercise capacity (see
Chapters 2.2 and 2.7.1);
† To recognize the characteristics of the athlete’s heart;
† To appropriately detect contraindications to exercise/competition,
and appropriately provide non-contraindication certificates.
Knowledge
† Exercise and sports physiology;
† Benefits of exercise training;
† Safety issues in exercise and sport;
† Diagnostic criteria and appropriate investigations in athletes with
cardiovascular disease;
† Risk factors for and mechanisms of sudden cardiac death (SCD)
during and after strenuous exercise;
† Specific population challenges and exercise programmes in
appropriate settings;
† Recommendations for professional and recreational sports
participation;
† SCD in patients, athletes, and in the population at large, and
† Mechanisms of action of illicit drugs.
Skills
The ability to:
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† perform an individual CVD risk assessment using appropriate
information from history, laboratory assessment including full
lipid profile and clinical data (see Chapter 2.7.1);
† recognize pathological cardiovascular changes and differentiate
them from the characteristic features of ‘athlete’s heart’; and
† use prevailing recommendations for eligibility for participation in
competitive sports.
Behaviours and attitudes
Recognition of
† The role of active lifestyle, exercise, and sport in the promotion of
health and in the prevention of the most threatening diseases
including cardiovascular diseases.
2.19.2 Cardiac rehabilitation
Objectives14
† To evaluate and manage cardiovascular risk. See Chapter 2.7.1;
† To evaluate exercise capacity and causes of exercise intolerance.
See Chapter 2.2;
† To provide appropriate rehabilitation and secondary prevention
to patients with cardiovascular diseases.
Knowledge
† Multi-disciplinary risk factor intervention;
† Definition of comprehensive cardiovascular prevention and
rehabilitation;
† Effects of behavioural change, including physical activity, nutrition,
educationandpsychosocial risk factorsonqualityof life, cardiovas-
cular risk, and outcome;
† Rehabilitation as a component of cardiac care and a promoter of
secondary prevention;
† Target populations and risk stratification of patients;
† Psychological aspects of rehabilitation and exercise practice.
Skills
The ability to:
† take a relevant history and perform an appropriate clinical exam-
ination including the specific evaluation of the elderly patient;
† perform and interpret risk stratification using indicated tests;
† interpret a cardiopulmonary exercise test and distinguish different
causes of exercise limitation;
† prescribe exercise-based rehabilitation programmes and other
lifestyle interventions according to the patient’s condition, in
collaboration with other specialists when necessary; and
† motivate the patient to ensure long-term adherence to lifestyle
changes and continuing exercise programmes.
Behaviours and attitudes
Recognition of:
† rehabilitation as a component of cardiac care;
† the importance of rehabilitation and secondary prevention for
professional, personal and social life among patients with heart
disease;
† the interplay of physical and psychological aspects of heart disease
and the positive influence of exercise on cardiovascular risk
factors;
† the role of other professionals including nurse specialists, phy-
siotherapists, ergophysiologists, psychologists, dieticians, and
general practitioners in rehabilitation and secondary prevention; and
† the importance of patient and family education, and the role of
other professionals in rehabilitation.
2.20 Arrhythmias
Objectives32,34
† To assess and treat patients with arrhythmias and conduction
disturbances.
Electrophysiology
† To select patients with an indication for electrophysiological
evaluation;
† To have a good understanding of diagnostic and therapeutic
electrophysiology.
Pacing32
† To select patients with an indication for pacing;
† To perform temporary pacing;
† To have a good understanding of pacemaker implantation, device
programming, and follow-up.
Implantable cardioverter defibrillator (see Chapter 2.17)5
† To select patients with an indication for an ICD;
† To have a good understanding of ICD implantation, device
programming, and follow-up.
Cardiac resynchronization therapy (see chapter 2.17)5,32
† To select patients with an indication for CRT;
† To have a good understanding of CRT implantation, device
programming, and follow-up.
Genetics
† To diagnose and treat inherited arrhythmogenic disease, request
genetic testing when appropriate, and counsel index case and
family members.
Knowledge
† Classification and definition of:
(a) bradycardias;
(b) tachycardias
(i) supraventricular arrhythmias including atrial fibrillation
and flutter;
(ii) ventricular arrhythmias.
† Epidemiology, pathophysiology, diagnosis, and clinical features of
arrhythmias and conduction disturbances;
† Inherited arrhythmogenic diseases;
† Prognosis including risk evaluation;
† Principles of electrocardiography and electrophysiology, and
relevant findings in different arrhythmias;
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† High-risk features in the resting ECG such as long QT, short QT,
Brugada ECG pattern, arrhythmogenic cardiomyopathy, and
cathecholaminergic ventricular tachycardia;
† Pharmacology of anti-arrhythmic drugs and knowledge of
pro-arrhythmic effects of cardiovascular and other drugs and
substances;
† Prevention of thrombo-embolic complications of atrial fibrillation
and flutter;
† Invasive and device management of arrhythmias, including
catheter ablation, and pacemaker, ICD, and surgical therapy;
† Importance of co-existing structural heart diseases, including
coronary artery disease, in relation to the outcome and manage-
ment of arrhythmias.
Skills
The ability to:
† take a relevant history and perform an appropriate clinical
examination;
† classify arrhythmias from 12-lead electrocardiography;
† manage acute arrhythmias with drugs;
† manage acute arrhythmias with cardioversion;
† prescribe appropriate preventive pharmacological therapy;
† perform and interpret electrocardiographic monitoring (Holter
and other long-term ECG recordings);
† interpret an electrophysiological study;
† identify and refer appropriate patients for catheter ablation and
perform follow-up after catheter ablation;
† recognize indications for genetic screening for inherited arrhyth-
mogenic diseases (channellopathies and cardiomyopathies).
Pacing, ICD, and CRT
The ability to:
† carry out temporary pacing;
† follow-up patients with pacemakers. Referral of patients to a
tertiary expert centre in case of troubleshooting not due to
battery exhaustion;
† basic follow-up of ICDs and CRTs in close collaboration with a
tertiary expert centre.
Behaviours and attitudes
† Appreciation of the anxiety suffered by patients undergoing inva-
sive arrhythmia management. Special emphasis should be given to
patients with ICDs and having undergone repeated defibrillation
shock therapy;
† Understanding of the palliative nature and potential adverse
effects of pharmacological and non-pharmacological therapies;
† Team working with electrophysiologists and heart failure specia-
lists for the follow-up of patients with device therapy.
2.21 Atrial fibrillation and flutter
Objectives6,35
† To carry out specialist assessment and treatment of patients with
atrial fibrillation and atrial flutter (AF).
Knowledge
† Epidemiology, pathophysiology, and prognosis of AF;
† Classification of AF;
† Diagnosis, clinical features, and impact on quality of life;
† Pre-disposing conditions;
† Importance of co-existing structural heart diseases on the
outcome, and their implications for the management of AF;
† Diagnostic procedures tailored to the individual need;
† Diagnosis and prevention of atrial thrombosis and embolic
complications,
– Use of embolic risk scores and bleeding risk scores.
† Indications, contraindications, side-effects, and complications of:
– antithrombotic therapy (including vitamin-K antagonists,
thrombin receptor antagonists, factor Xa antagonists, and
low-molecular-weight heparins);
– rhythm vs. rate control therapy;
– anti-arrhythmic drug therapy;
– pharmacological cardioversion;
– prevention of recurrences;
– pharmacological control of ventricular rate;
– direct current (DC) cardioversion;
– Pacemaker and ICD therapy;
– catheter ablation of AF;
– surgical ablationofAFandocclusionof the left atrial appendage;
– catheter ablation of the AV node;
– atrial appendage occlusion devices.
Skills
The ability to:
† take a relevant history and perform an appropriate clinical
examination;
† perform and interpret investigations including
– electrocardiography;
– echocardiography (TTE and TOE);
– prolonged ECG monitoring (e.g. Holter monitoring);
– exercise testing;
† apply scores for the assessment of thrombotic and bleeding risks;
† implement appropriate antithrombotic strategies for prevention
of ischaemic stroke and systemic embolism;
† select patients for appropriate treatment as listed in knowledge;
† perform independently
– antithrombotic therapy;
– switch from one antithrombotic drug to another;
– rhythm vs. rate control therapy;
– anti-arrhythmic drug therapy;
– pharmacological cardioversion;
– pharmacological control of ventricular rate;
– DC cardioversion.
Behaviours and attitudes
† Appreciation of patients’ anxiety in relation to palpitation, anti-
coagulant therapy, and invasive methods of management;
† Appreciation of the limitations and potential risks of anti-
arrhythmic drug therapy;
† Appreciation of the importance of anticoagulant therapy;
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† Appreciation of the limitations and potential risks of device
therapies;
† Recognition of the importance of patients’ and carers’ education
and information;
† Team working with general practitioners, nurses, electrophysiol-
ogists, surgeons, haematologists, and other healthcare providers.
2.22 Syncope
Objectives36
† To define syncope;
† To differentiate syncope from the other causes of transient loss of
consciousness;
† To assess and treat patients with syncope.
Knowledge
† The epidemiology and prevalence of different causes of syncope;
† The pathophysiology of syncope;
† Causes of syncope and other forms of transient loss of
consciousness;
† Risk stratification of patients with syncope and indications for
hospitalization;
† Diagnostic evaluation
(a) history from patient and eye-witnesses with special emphasis
on the circumstances of the event;
(b) initial evaluation (physical examination, baseline ECG);
(c) appropriateness of additional testing:
(i) carotid sinus massage;
(ii) orthostatic challenge;
(iii) echocardiogram;
(iv) exercise stress testing;
(v) tilt testing;
(vi) electrocardiographic monitoring (long-term ECG);
(vii) cardiac catheterization and coronary angiography;
(viii) electrophysiological testing.
† Treatments (device based, pharmacological or physical man-
oeuvres) for:
(a) neurally mediated (reflex) syncope;
(b) orthostatic hypotension;
(c) cardiac arrhythmias (tachy and brady);
(d) structural cardiac or cardiopulmonary disease.
Skills
The ability to:
† take a relevant history and perform an appropriate clinical
examination;
† perform or interpret the tests listed above;
† perform risk stratification;
† select appropriate treatment:
education and reassurance
– physical manoeuvres;
– drug therapy;
– device implantation.
Behaviours and attitudes
† Understanding of the impact of syncope on the patient’s lifestyle;
† Appreciation that syncope can be a transient symptom, and ac-
ceptance that it is not necessarily a disease;
† Willingness to collaborate with neurologists, elderly care specia-
lists, and other care providers;
† Acceptance that the diagnosis of syncope is often presumptive;
† Recognition thatmanypatients donot need any specific treatment
apart from education and reassurance;
† Appreciation that therapies are often ineffective;
† Balance in assessing the risk–benefit and the cost-efficacy of pace-
maker, ICD, and catheter ablation therapy.
2.23 Sudden cardiac death and
resuscitation
Objectives
Sudden cardiac death34
† Tomanage patientswith aborted SCD, thosewith life-threatening
arrhythmias and others with increased risk of SCD.
Resuscitation
† To be able to carry out basic (BLS) and ACLS.
Knowledge
Sudden cardiac death
† Definition of SCD;
† Epidemiology, aetiology, pathology, pathophysiology, and clinical
presentation of pre-disposing conditions;
† Diagnostic work-up and risk stratification of survivors;
† Selectionof appropriate long-termmanagementoptions including
pharmacological and device-based therapies;
† Current recommendations for primary and secondary prevention
of SCD;
† Identification, risk stratification, and management of individuals at
elevated risk, including family members of SCD patients.
Resuscitation
† Causesof cardiorespiratoryarrest, identificationofpatients at risk,
and early implementation of corrective treatment of reversible
causes;
† Methods and guidelines of basic and advanced life support, includ-
ing airway management, appropriate drug use, defibrillation, and
pacing;
† Indications for not starting resuscitation or ceasing an initiated
attempt;
† Pharmacology, actions, indications, and contraindications of the
main drugs used in the management of a cardiac arrest.
Skills
Sudden cardiac death
The ability to:
† take a relevant history and perform an appropriate clinical
examination;
† risk-stratify using the following techniques: echocardiography,
ECG, Holter ECG, exercise testing;
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† refer to tertiary centre for other forms of long-term ECG moni-
toring, catheterization and coronary angiography, electrophysio-
logical study, and heart rate variability;
† follow-up SCD survivors.
Resuscitation
The ability to:
† quickly identify the cause of collapse;
† performBLS andACLS life support, including emergency andperi-
resuscitation echocardiography;
† lead and coordinate the actions of an ACLS team;
† teach BLS.
Behaviours and attitudes
Sudden cardiac death
† Awareness of the importance of prodromal symptoms and signs;
† Appreciation of SCD survivor and family anxieties;
† Appreciation of the importance of patient education and second-
ary prevention;
† Understanding of the medical, psychological, and social problems
arising in patients with frequent ICD activation;
† Awareness of the importance of considering a switch to palliative
care in heart failure patients with an ICD.
Resuscitation
† Recognition of the urgency of the management of cardiac arrest;
† Appreciation of the importance of working in a team with lay
persons, paramedics, and othermedical personnel during resusci-
tation (BLS and ACLS);
† Understanding of the importance of regular audit of the basic and
advanced life support programme.
2.24 Diseases of the aorta and trauma to
the aorta and heart
Objectives37
† To assess diseases of the aorta, and trauma to the aorta and heart;
† To implement appropriate medical therapy, and recognize the
indications for interventional or surgical treatment.
Knowledge
† epidemiology, aetiology, pathology, genetics, pathophysiology,
and clinical presentations of aortic disease, aortic root disease,
and trauma to the aorta and heart including:
– aneurysm of the thoracic aorta;
– classification of aortic dissection;
– Leriche syndrome;
– aortic atherosclerosis types I– IV;
– inflammatory aortic disease;
– genetic conditions associated with aortic syndromes;
– trauma of the heart including contusion and ACS;
– trauma of the vessels including acute aortic dissection and
aortic rupture.
† Strengths and limitations of different imaging modalities;
† Appropriate medical, interventional, and surgical management
strategies.
Skills
The ability to:
† take a relevant history and perform an appropriate clinical exam-
ination, including pulse and BP measurements in different arms
(and legs) and calculate for diagnostic purposes the ABI;
† recognize the need for and organize genetic and family screening
where appropriate;
† select and interpret imaging studies (see chapter 2.3): chest X-ray,
echocardiography (TTE, TOE), CMR, computed tomography,
intravascular ultrasound, and angiography of the aorta and the
heart;
† managedifferent aortic conditionswith the appropriate treatment
modality in a timely manner.
Behaviours and attitudes
† Team working with emergency and intensive care physicians,
cardiovascular surgeons, interventional cardiologists, and
radiologists;
† Recognition of the urgency required inmanaging patientswith dis-
eases of the aorta and cardiac trauma;
† Recognition of the need for long-term follow-up of patients with
chronic aortic disease.
2.25 Peripheral artery disease
Objectives38
† Toassess andmanagepatientswithPAD, including atherosclerotic
and other diseases of the cervical (carotid and vertebral), mesen-
teric, renal, upper and lower limb arteries.
Knowledge
† Epidemiology and pathology of PAD;
† Diagnosis and assessment of PAD, including the ABI and various
imaging modalities;
† General treatment modalities including smoking cessation, life-
style modification, supervised exercise training programme, anti-
platelet and anti-thrombotic drugs, lipid-lowering drugs, and
antihypertensive therapies in patients with PAD;
† Indications for invasive (interventional and surgical) management
and their relative merits in different situations;
† Prognostic stratification of PAD;
† Acute and critical limb ischaemia management.
Skills
The ability to:
† take a relevant history and perform an appropriate physical exam-
ination, especially the examination of peripheral pulses;
† identify the risk factors and select the appropriate management
strategy;
† perform and interpret vascular ultrasound screening of abdominal
aorta, carotid and femoral arteries;
† perform and interpret the ABI;
† interpret ultrasound, MR angiography, X-ray CT angiography, and
invasive angiography in different vascular beds;
† classify and stage lower extremity artery disease.
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Behaviours and attitudes
† Appreciation of the systemic nature of atherosclerosis and its
implications for a patient in whom disease is manifested within a
single territory. In particular, awareness of the association of
PAD with disease in the coronary, carotid, and renal arteries;
† Recognition of the importance of risk-factor modification in
prevention;
† A positive approach to encouraging patients to adopt a healthier
lifestyle with specific emphasis on risk factors and walking;
† Team working with specialists such as cardiac rehabilitation spe-
cialists, interventional cardiologists, radiologists, vascular sur-
geons, and diabetologists.
2.26 Thrombo-embolic venous disease
Objectives39
† To diagnose, treat and prevent:
– deep vein thrombosis;
– pulmonary embolism.
Knowledge
† Epidemiology of deep vein thrombosis;
† Risk factors for deep vein thrombosis
– inherited thrombophilia (e.g. factor V Leiden and prothrombin
gene mutations);
– acquired thrombophilia (e.g. major surgery, trauma, immobil-
ization, lupus anticoagulant, andelevated levels of antiphospho-
lipid antibodies, malignancy, pregnancy, oral contraceptives,
and myeloproliferative disorders).
† Pathophysiology of pulmonary embolism
– increased pulmonary vascular resistance and ventilation–
perfusion mismatch.
† Clinical presentation of superficial and deep vein thrombosis;
† Clinical presentation of pulmonary embolism;
† Diagnosis of deep vein thrombosis
– Duplex examination of leg and pelvic veins.
† Diagnosis of pulmonary embolism by:
– D-dimer and troponins;
– ECG;
– computed tomography;
– echocardiography;
– ventilation–perfusion scan;
– MR angiography;
– pulmonary angiography.
† Diagnosis of deep vein thrombosis
– Ultrasound and Doppler imaging of leg and pelvic veins.
† Management of
– Superficial venous thrombosis;
– Deep vein thrombosis.
† Treatment of acute pulmonary embolism by:
– anticoagulant therapy;
– thrombolytic therapy;
– embolectomy.
† Management of chronic thrombo-embolic pulmonary hyperten-
sion, including thrombo-endarterectomy;
† Preventive measures for DVT/pulmonary embolism:
– compression stockings;
– prophylactic anticoagulant therapy;
– caval filter.
Skills
The ability to:
† take a relevant history and perform an appropriate clinical
examination;
† interpret ECG, computed tomography, echocardiography, and
ventilation–perfusion scanning signs of pulmonary hypertension
and pulmonary thrombo-embolism;
† select appropriate therapy for acute pulmonary embolism and
chronic thrombo-embolic pulmonary hypertension;
† diagnose and manage acute and chronic deep vein thrombosis;
† decide upon the duration of anticoagulant therapy for patients
with thrombo-embolic venous disease.
Behaviours and attitudes
† Appreciation of the difficulties in diagnosing pulmonary embolism
on the basis of symptoms and signs;
† Collaboration with other imaging experts including radiologists
and nuclear imaging specialists;
† Ensuring patient understanding of the disease and the importance
of compliance with, and the precautions required during long-
term anticoagulant therapy.
2.27 Acute cardiovascular care
Objectives
† To perform specialist assessment and management of patients
with cardiac emergencies;
† To be able to carry out basic (BLS) and ACLS. See Chapter 2.23;
† To collaboratewith cardiac intensive care unit (ICU) cardiologists
and intensive care physicians in the assessment and management
of cardiovascular diseases in patients in the ICU.
Knowledge
† The earlywarning signs and symptoms of impending critical illness;
† Causesof cardiorespiratoryarrest, identificationofpatients at risk,
and early implementation of corrective treatment of reversible
causes;
† Algorithms of basic (BLS) and advanced life support (ACLS),
including the indications for not starting resuscitation or ceasing
an initiated attempt. See Chapter 2.23;
† Criteria for admission and discharge from ICU;
† Epidemiology, pathophysiology, diagnosis and management of
cardiac emergencies, including ACS, acute heart failure, cardio-
genic shock, life-threatening arrhythmias, cardiac arrest and resus-
citation, pericardial tamponade, pulmonaryembolism, acute valve,
and aortic disease;
† Detailed and specialized cardiovascular support
– causes, diagnosis, consequences, and treatment of circulatory
failure and shock;
– indications, limitations, complications, and interpretation of
non-invasive and invasive haemodynamic monitoring;
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– pharmacology, indications, and contraindications of therapy
used to support thecirculation (fluids, inotropic, andvasoactive
drugs);
– indications for mechanical circulatory assist devices (ECMO,
IABP, and other assist devices);
– indications, contraindications, and complications of arterial and
central venous access;
– recognition and management of basic and complex arrhyth-
mias, including arrhythmias during resuscitation.
† Principles of respiratory support
– respiratory physiology and pathophysiology: gas exchange, O2
and CO2 transport, hypoxia, hypo- and hyper-capnoea;
– interpretation of arterial and venous blood gas samples;
– causes, prevention, andmanagement of respiratory insufficiency
– emergency airway management;
– principles of oxygen therapy and selection of oxygen adminis-
tration devices;
– knowledgeof the indications, selection, andmanagementof dif-
ferent methods of invasive and non-invasive mechanical venti-
lation (including the general principles of mechanical
ventilation and heart– lung interactions);
– effects of mechanical ventilation on the circulation;
– pathogenesis, diagnosis, prevention, and principles of therapy
for acute lung injury/acute respiratory distress syndrome
(ALI/ARDS).
† Principles of fluid, electrolyte, acid–base, and renal support
– renal pathophysiology, regulation of fluid, electrolyte, and
acid–base balance;
– causes, diagnosis, prevention, and general principlesofmanage-
ment of renal failure (acute, chronic, and acute on chronic);
– general knowledge of renal replacement therapies (haemofil-
tration and dialysis);
– treatment strategies for abnormalities of fluid, electrolyte,
acid–base balance;
– indications, contraindications, and complications of fluid
therapy;
– identification and prevention of the use or dose adjustments of
nephrotoxic drugs in patients with renal impairment or failure.
† Principles of metabolic and gastrointestinal support
– blood glucose control homeostasis: pathophysiology, indica-
tions for and monitoring of therapy;
– basic principles of gastrointestinal physiology, gut motility;
– assessment and management of nutritional status and basal
energy requirements;
– prevention of stress ulceration.
† Principles of prevention and treatment of infection
– epidemiology and strategies for infection prevention in the ICU;
– indications for microbiological sampling and interpretation of
microbiological test results;
– selection, indications, complications, interactions, and moni-
toring of common antimicrobial drugs;
– basic knowledgeof sepsis, septic shock, and systemic inflamma-
tory response syndrome.
† Other principles of support
– causes, signs and symptoms, consequences, and methods of
assessment of impaired neurological function;
– pain assessment and control (appropriate analgesia);
– drug therapy and assessment methods for sedation;
– drug therapy and assessment methods for pain.
Skills
The ability to:
† perform BLS and ACLS, and manage the patient in the post-
resuscitation period;
† develop a structured approach to identify, manage, and stabilize
the patient with haemodynamic instability;
† use emergency monitoring equipment and to timely identify car-
diovascular abnormalities requiring urgent intervention;
† participate in the decisions to admit, discharge, or transfer patients
from the ICU.
† Cardiovascular system support
– perform arterial, central venous, and pulmonary artery cath-
eterization;
– measure and interpret haemodynamic variables;
– use echocardiography appropriately in the acute and intensive
care patient, including emergency and peri-resuscitation echo-
cardiography, as an independent operator;12
– initiate emergency cardiac pacing, either transvenous or trans-
thoracic;
– perform pericardiocentesis;
– treat and manage basic and complex arrhythmias in the acute
care patient;
– select and use fluids, inotropic, vasoactive, and anti-arrhythmic
drugs.
† Respiratory system support:
– identify the early signs of acute airway insufficiency and acute
respiratory failure;
– perform emergency tracheal intubation;
– obtain and interpret data from blood gas samples (arterial,
central, and mixed venous).
† Comply with local infection control measures and appropriately
manage antimicrobial drug therapy;
† Correct fluid, electrolyte, metabolic, and glucose disorders;
† Assess neurological function (e.g. Glasgow Coma Scale).
Behaviours and attitudes
† Address the physical and psychosocial consequences of critical
illness for patients and their families;
† Manage end of life situations and participate in the process of
withholding or withdrawing treatment in cooperation with the
multi-disciplinary team;
† Communicate, collaborate and team-work with the health care
team (nurses in the ICU, ICU cardiologists, intensivists and
paramedical staff);
† Readiness for quick availability, when requested by physicians,
nurses, or staff.
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2.28 The cardiac consult
2.28.1 The patient undergoing non-cardiac surgery
Objectives40
† To cooperate with and assist other medical specialists in the pre-
vention, assessment, and management of cardiovascular diseases
in patients requiring non-cardiac surgery;
† To perform an individualized cardiac risk assessment in patients
to be submitted to non-cardiac surgery;
† To perform an integrated multi-disciplinary pre- and peri-
operative approach, in close cooperation with anaesthetists, but
also with surgeons, other medical specialists, and paramedical
professionals;
† To optimize the patient’s pre-operative condition before non-
cardiac surgery.
Knowledge
† Pathophysiology of systemic and cardiovascular stress responses
to surgery;
† Pathophysiology of cardiovascular complications during surgery
such as peri-operative infarction, rhythm disturbances, and heart
failure;
† Patient-related, cardiac-related, and surgery-specific risk factors
that influence cardiac risk for non-cardiac surgical interventions;
† Effects ofmost frequently used anaesthetic and sedative agents on
cardiovascular function;
† Indications for and limitations of non-invasive testing for cardiac
disease before surgery including ECG, echocardiography, various
stress testing modalities, and X-ray computed tomography;
† Indications for pre-operative coronary angiography;
† Benefits of and clinical indications for pharmacological risk reduc-
tion strategies before and during surgery (beta-blockers, statins,
antiplatelet therapy);
† Insight on alternative types of surgical procedure and local or re-
gional anaesthetic techniques that can reduce cardiovascular risk;
† Indications for prophylactic myocardial revascularization before
surgery;
† Role of monitoring techniques for peri-operative cardiac events;
† Risk evaluation, timing of procedure and risk reduction strategies
in patients with specific conditions such as: post-revascularization
(PCI or surgery), heart failure, valve diseases, valve prostheses,
rhythm disturbances, and cardiac devices (ICDs and pacemakers).
Skills
The ability to:
† perform an individualized cardiac risk assessment by applying risk
stratification indices according to the patient’s clinical condition,
type and urgency of surgery;
† select, perform, and interpret the non-invasive diagnostic tests
before surgery (ECG, echocardiography, stress testing);
† discuss with the anaesthetist the peri-operative management
regarding the type of surgery, anaesthetic technique, and peri-
operative surveillance;
† select and implementthepharmacological andnon-pharmacological
interventions that can reduce cardiac risk during surgery;
† decide on the best timing of surgery and indicate the type of
anti-thrombotic therapy in patients following revascularization
procedures, in whom surgery cannot be delayed;
† check andoptimize the control of all cardiovascular risk factors for
long-term cardiovascular disease prevention;
† identify the need for cardiac follow-up after surgery.
Behaviours and attitudes
† Stimulation of multi-disciplinary team discussions on cardio-
vascular disease assessment and peri-operative strategies and
management;
† Development and implementation of multi-disciplinary protocols
for cardiovascular disease assessment and management;
† Awareness of the current cardiovascular prognosis of patients for
whom non-cardiac surgery is planned.
2.28.2 The patient with neurological symptoms
Objectives
† To search for potential sources of cardiac embolism and other
manifestations of atherosclerosis (coronary heart disease or
peripheral arterial disease) in patientswith ischaemic neurological
symptoms and advise on appropriate short- and long-term
management (secondary stroke prevention);41
† To cooperate with neurologists in the evaluation of patients with
other neurological presentations such as syncope, dizziness,
haemorrhagic stroke (secondary to hypertension, antiplatelet,
or anticoagulant therapy), and neuromuscular diseases with
possible cardiac involvement.
Knowledge
† Mechanism, epidemiology, clinical characteristics, and potential
treatment options in patients with cardiac and aortic sources of
embolism;
† Atherosclerosis as a systemic disease involving (simultaneously)
other vascular territories;
† Importance and urgency of stroke prevention (anticoagulation) in
patients with AF and fibrillation;
† Pharmacological andnon-pharmacological therapies, including the
indications for and relative merits of carotid interventions (end-
arterectomy vs. stenting);
† In patients with non-ischaemic neurological manifestations:
– the various causes of transient loss of consciousness;
– the diagnosis and medical treatment of haemorrhagic stroke.
Insight into the indications for neurosurgical interventions;
– management of anticoagulant or antiplatelet therapy pre-
scribed for cardiac conditions in patients with ischaemic or
haemorrhagic stroke;
– the pathophysiology, epidemiology, recommended cardiac
evaluation, and management of patients with neuromuscular
disorders involving the heart.
Skills
The ability to:
† use echocardiography, including trans-oesophageal echocardiog-
raphy, and other techniques to search for potential sources of
embolism;
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† use ultrasound examination of the cervical arteries;
† define the need for further diagnostic work-up to search for other
atheroscleroticmanifestations, and adviseon appropriate therapy;
† implement secondary prevention strategies, including lifestyle and
pharmacological therapies.
Behaviours and attitudes
† Close team-work with neurologists and radiologists to determine
the best management strategy for patients with ischaemic and
non-ischaemic neurological conditions.
2.28.3 The patient with conditions not presenting primarily
as cardiovascular disease
Objectives
† To manage cardiovascular disease in patients with diseases of
other organs or systems that affect the cardiovascular system or
are associated with cardiovascular involvement;
† To be particularly vigilant in the elderly, in patients with diabetes
types I and II, chronic kidney disease, pulmonary disease, erectile
dysfunction, and rheumatic disorders.
Knowledge
Diabetes20
† Definition, classification, epidemiology, pathophysiology, compli-
cations, and principles of therapy in diabetes;
† Diabetes as a cardiovascular risk equivalent and as a risk factor for
heart failure (diabetic cardiomyopathy);
† Specificities of cardiovascular management in diabetic patients
(e.g. revascularization strategies);
† Cardiovascular effects of antidiabetic drugs.
Chronic kidney disease
† Pathophysiology, epidemiology, and clinical implications of the
complex interplay between the heart, the vasculature, and CKD
(as both a risk factor and a consequence of cardiovascular disease)
† Clinical cardiac evaluation in patients with advanced CKD;
† Importance of appropriate renal function evaluation in every
patient with cardiac disease;
† Primary and secondary pharmacological prevention of CKD
(RAS inhibition);
† Pharmacological specificities (indications, contraindications, and
dose adjustment) of cardiovascular drugs in patients with CKD;
† Strategies to avoid contrast nephropathy induced by cardiological
examinations.
Others
† Epidemiology and clinical manifestations of, and treatment strat-
egies for cardiovascular diseases in elderly patients and those
with pulmonary diseases, erectile dysfunction, rheumatic disor-
ders and other coexisting diseases.
Skills
The ability to:
† prevent, identify, and stratify the risk of cardiovascular disease
including the specific evaluation of the elderly patient;
† provide appropriate counselling on diagnostic and therapeutic
strategies;
† counsel the patient on long-term risk reduction.
Behaviours and attitudes
† Use of the cardiac consultation as an opportunity to identify
cardiovascular risk factors and provide recommendations to the
patient on lifestyle and medical therapy.
Supplementary material
Supplementary material is available at European Heart Journal online.
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